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1. Introduction  
1.1 The role of peptides in therapy 
A thorough inspection of pharmacy shelves could one let perceive that commonly 
marketed drugs are either ‘small-molecule’ chemicals or high molecular weight biologics, 
the latter mostly being proteins. There is however a third group with a molecular weight 
in the medium range (500 – 5000 Da), i.e. peptide-based drugs, which are gradually 
moving to the front stage.1 Peptides are set apart from proteins in that they are 
composed of less than 50 amino acids.2 Peptides that occur in nature as secondary 
metabolites, such as daptomycin and cyclosporine, are furthermore characterized by the 
unusual amino acid building blocks like D-amino acids and N-methylated amino acids. 
Physiological peptides are known to be involved in many processes, e.g. acting as signals 
as in the case of cytokines, neurotransmitters as for example galanin or hormones like 
somatotropin.3 Since most biological targets, referred to as drug targets in pharmacy, are 
proteins, e.g. enzymes, ion-channels and receptors, peptidic natural products may be 
envisaged as prospective ligands. Additionally, they may exhibit target specificity and 
hence minimal toxicity, the latter is also credited to there sound metabolism to the 
constituent amino acids which are readily cleared from the body with minimal tissue 
build-up.4 
Peptide chemists, inspired by the structure and function of peptides isolated from natural 
sources, were successful in synthesizing peptide analogues through chemical or biological 
synthesis.5 However there is still the need for new peptide scaffolds, able to serve as drug 
leads that may have arisen from natures biosynthetic machineries. This calls for the 
dedicated work of natural product chemists in isolating and characterizing such peptides, 
further exploring them deeper to understand their biosynthesis and biological activities 
and later on to be implemented in the drug-design process.  
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Fig 1-1. Peptide secondary metabolites. 
1.2 Peptides from fungi 
Peptides are produced by prokaryotes and eukaryotes alike.6 The fungal kingdom is 
regarded as a rich source to be investigated further for the production of secondary 
metabolites including peptides. Their structures were refined through years of evolution, 
since these compounds are important for the survival and growth of the producers in 
their rivalry natural habitat. Such compounds may act as siderophores, toxins or signaling 
molecules for communication.7 From a human point of view, fungi are double-faced 
organisms, their dark-side being associated with their disease-causing or putrescent 
properties, some of these properties being attributed to their metabolite production, e.g. 
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mycotoxins. However, fungal metabolites provide us already today with important drugs, 
e.g. lovastatins, and are of importance for our future drugs.8   
 
Fig 1-2. Fungal metabolite used as drug. 
1.2.1 Fungal peptides assembly lines 
Fungal peptides are assembled either through the ribosomal machinery, i.e. through 
direct gene translation, including the amatoxins and phalloidin,9 or by multi-modular non-
ribosomal peptide synthetases (NRPS), the later accounting for most of the isolated 
fungal peptides.10 These are megaenzymes divided into modules termed initiation and 
elongation modules where each module is responsible for integrating an amino acid into 
the growing peptide chain. This is done with the help of catalytic domains, a subdivision 
of each module. Fundamental domains are indispensable for the selection and activation 
of the building blocks (adenylation, A-domain), the tethering of the product to the 
enzyme (peptidyl carrier protein, PCP-domain) and peptide bond formation 
(condensation, C-domain). Structural diversity arises due to the presence of auxillary 
domains imparting unique structural features to the non-ribosomal peptides. These 
include epimerization (E) domains for incorporating D-amino acids, N-methylation (N-Mt) 
and C-methylation (C-Mt) domains for introducing methyl groups, formylation (F) domain 
for introducing formyl groups and  oxidation (Ox) and reduction (R) domains for 
formation of thiazoles, oxazoles and thiazolidines, oxazolidines, respectively.11 While 
bacterial NRPS feature a thioesterase (TE) domain at the end of the NRPS template to 
catalyze peptide release and cyclization, fungal NRPS employ an alternative enzymatic 
cyclization strategy with the help of a condensation like CT-domain.
12 Based on the type of 
cyclization linkage, fungal cyclic peptides are classified into homodetic cyclic peptides, 
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whose ring is solely composed of normal peptide bonds arising from head-to-tail 
cyclization, heterodetic cyclic peptides featuring other covalent bonds during cyclization, 
e.g. depsipeptides, and complex cyclic peptides combining both types of linkage, e.g. 
bicyclic peptides.13  
 
Fig 1-3. Ribosomally synthesized fungal peptides. 
Fungal NRPS are classified into 3 major classes based on genetic studies of the domain 
architecture and the end peptide produced.14 Type A with a linear NRPS template, as seen 
for the δ-(L-α-aminoadipyl)-L-cysteine-D-valine (ACV) synthetase and cyclosporine 
synthetase which are responsible for the production of the penicillin core structure and 
cyclosporine, respectively. Here the sequence of the end peptide is easily forecasted from 
the module architecture, as each module is responsible for incorporating a single amino 
acid building block. The second class is type B with an iterative NRPS template, where the 
modules are repetitively being used during peptide assembly, e.g. enniatin synthetase 
(ES). Lastly type C with a non-linear NRPS template, featuring an irregular domain 
architecture, from which the end peptide could not be inferred. So far, most studied 
fungal NRPS belong to the first 2 classes, whereas products of the last class have not been 
isolated so far. This is imminent to change, as fungal genes are increasingly being 
sequenced with the aim to explain fungal NRPS enzymology and probably isolate more 
secondary metabolites. 
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1.2.2 Fungal non-ribosomal peptides 
Fungal non-ribosomal peptides share common structural features making them 
interesting drug scaffolds:  
1. A cyclic architecture, bestowing several attractive attributes such as structural 
rigor eliciting better target binding and thus specific and enhanced biological 
activity. Stitching the loose ends, normally targeted by proteolytic enzymes, gives 
them added stability against enzymatic degradation. Moreover, masking of the 
charged termini, infers better membrane permeability.15  
2. N-methylation of the peptide skeleton imposes steric hindrance about the N-
methylated peptide bond which effects the whole peptide conformation. This 
plays an additional role in receptor affinity and selectivity. Replacing a hydrogen 
with a methyl group effects the hydrogen-bonding capabilities of the peptide, i.e. 
intra and intermolecular bonding. This is speculated to play a role in improving 
intestinal permeability and thus enhancing oral bioavailability, although the exact 
mechanism is still not clear.16 
3. Presence of atypical building units, aside from the known L-configured 20 amino 
acids, such as D-amino acids, non-proteinogenic amino acids and carboxy acids, 
further improves their proteolytic stability.17  
Due to these advantages, peptide-based drugs from fungal origin are employed since 
some time as extremely valuable drugs. 
1.2.3 Fungal peptides as drugs 
The β-lactams, ‘a story that never grows old’ 
The antibiotic era was shaped by the fortunate discovery of penicillin, a non-ribosomal 
cyclic tripeptide isolated from Penicillium sp. in 1928, which played a pivotal role in saving 
the life’s of hundreds from infection.10 Since then, the search for antibiotics from 
microorganisms is commonplace, due to the development of resistance. The 
cephalosporins, a ring expanded form of the penicillins, were later isolated from 
Cephalosporioum acremonium obtained from a water sample off the coast of Sardinia in 
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1949, which is the first metabolite to be isolated from a water source.18 Both penicillins 
and cephalosporins follow a similar biosynthetic route from the tripeptide δ-(L-α-
aminoadipyl)-L-cysteine-D-valine (ACV) assembled by ACV synthetase. With the help of 
isopenicillin-N-synthase (IpnA), cyclization of the linear tripeptide gives the famous β-
lactam nucleus, isopenicillin-N. Isopenicillin-N, a common intermediate for both 
antibiotics, acts as a branching point from which the complete biosynthesis of penicillin 
and cephalosporin is further realized using several more synthases.19 β-lactams exert 
their anti-bacterial activity through irreversibly inhibiting the penicillin binding protein 
(PBP), responsible for cross-linking of the growing peptidoglycan layer of bacterial cell 
wall.20 
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Fig 1-4. Biosynthetic route for β-lactam antibiotics, penicillin G and cephalosporin C (adopted from 
literature).
19 
To this day, both antibiotic peptide classes have been modified in several ways, through 
synthetic and semi-synthetic approaches, to provide us with more potent and superior 
analogues in terms of improved pharmacokinetics and antibiotic activity. The latest 5th 
generation cephalosporin antibiotic ceftaroline fosamil (Zinforo®), active against MRSA, 
was recently approved in the European Union in 2012 and many more are in the pipeline, 
indicating that a lot could still be derived from the β-lactam nucleus. 21,22 
 
Fig 1-5. Ceftaroline fosamil a fifth generation cephalosporin antibiotic. 
Cyclosporine peptides more than just immunosuppressants 
Customary organ transplantation success is credited to cyclosporine A (Fig 1-1), a cyclic 
non-ribosomal undecapeptide, originally isolated in 1972 from Tolypocladium inflatum. It 
consists of several N-methylated amino acids, D-amino acid, i.e. D-alanine, as well as 
unusual amino acids such as L-α-aminobutyric acid and butenylmethyl-threonine. Its 
immunosuppressive property is due to its high affinity binding to cyclophilins in T-cells, 
inhibiting calcinuerin, a protein phosphatase, responsible for activation of NFAT (Nuclear 
factor of activated T-cells), a transcription factor that stimulates the expression of IL-2 
(Interleukin 2), a cytokine signaling molecule, hence repressing the activity of the T-cells, 
an integral part of the immune system.23 It is originally marketed as oral and intravenous 
formulations for use in organ transplantation, rheumatoid arthritis and psoriasis 
(Neoral®), with total net sales in 2013 exceeding 750 million USD.24 A new formulation, 
ophthalmic emulsion (Restasis®), was launched in 2002 for the treatment of dry eyes.25 
Voclosporin, a cyclosporine A analogue with a single modified amino acid, was granted 
orphan designation for treatment of non-infectious uveitis, and is now in phase 2b clinical 
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trials for treatment of lupus nephritis.26 Alisporivir, a second-generation cyclophilin 
inhibitor, synthetically modified from cyclosporine A but lacking immunosuppressive 
activity,27 is currently in phase 3 clinical trials for AIDS treatment and is in phase 2 clinical 
trials for treatment of hepatitis C.24 
 
Fig 1-6. Cyclosporine peptide analogues in clinical trials. 
The ‘Penicillin of anti-fungals’ 
Echinocandins are the most recent clinically approved antifungal drug class, comprising 
the caspofungin, micafungin and anidulafungin. All are semi-synthetic analogues of the 
natural echinocandin B, isolated from Aspergillus nidulans in 1974, not clinically 
applicable due to its hemolytic activity. Echinocandins are cyclic lipo-hexapeptides with an 
N-linked fatty acyl side chain, along with several hydroxylated non-proteinogenic amino 
acids.28  
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Fig 1-7. One of the first naturally isolated echinocandins. 
Echinocandin biosynthesis is achieved by a six-module non-ribosomal peptide synthetase 
EcdA, along with several additional synthetases, such as EcdI for incorporating fatty 
acids.29 They are considered the ‘penicillin of antifungals` due to their exclusive mode of 
action targeting fungal cell wall, not the case for older antifungals. They non-
competitively inhibit the β-1,3-D-glucan synthase, responsible for the biosynthesis of an 
integral part of fungal cell wall. Their mode of action makes them selective to fungal cell 
wall with no effect on mammalian host cells, in view of their different cell wall 
construction. They thus exhibit good safety and tolerability profiles with minimal toxicities 
and drug interactions. They are fungicidal against Candida sp., including azole-resistant 
strains, and fungistatic against Aspergillus sp..30 Unfortunately, echinocandins are not 
orally bioavailable and have to be administered intravenously; this incites organic 
chemists in finding newer analogues that can overcome this formulation shortcoming. 
Aminocandin a new member of this class in clinical trials has a longer half-life, and hence 
may partially avoid the common drawback of a daily intravenous administration, allowing 
an extended dosing interval.31  
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Fig 1-8. Approved semi-synthetic echinocandin antifungal drugs on the market. 
The emerging increase in fatal invasive fungal infections, and the limited antifungal drug 
classes clinically at hand, calls upon the urgent intervention to introduce newer 
antifungals.32 Echinocandins being the first antifungal drug class to target cell wall 
biosynthesis, prompted the interest in searching for newer antifungal drugs with a similar 
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mode of action, favorably orally administered. Recently, a semi-synthetic enfumafungin 
derivative MK-3118, a fungal triterpenoid glycoside, is in clinical trials as an orally active 
antifungal, similarly targeting the β-1,3-D-glucan synthase.33  
 
Fig 1-9. Newer antifungal drugs in clinical trials targeting the β-1,3-D-glucan synthase. 
Fungal cyclic hexadepsipeptides 
The enniatins are a family of cyclohexadepsipeptides initially isolated from Fusarium sp., 
but also produced by other fungal genera. So far 29 enniatins have been isolated, all 
featuring three N-methyl-L-amino acids, such as valine, leucine and isoleucine, and three 
D-hydroxyacids, with alternating ester and amide bonds forming a ring structure.34 They 
are biosynthesized in an iterative manner with the help of the enniatin synthetase (ES), a 
two-module multienzyme, showing flexible substrate selectivity incorporating variable 
amino acids, which explains the structural diversity of the enniatins.35 Beauvericin and 
destruxin are other fungal cyclohexadepsipeptides, structurally related to the enniatins, 
which were originally isolated from the entomopathogenic fungi Beauveria bassiana and 
Metarhizium anisopliae respectively.36,37 
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A characteristic feature of these fungal cyclohexadepsipeptides is their ionophoric 
activity. They form cation selective pores or channels, which disturbs the cell’s normal ion 
balance and thus disrupt the cell membrane integrity leading to cell death. This 
mechanism is suggested to account for their wide range of interesting biological activities, 
including insecticidal, anti-microbial, cytotoxic and anti-viral activity, nominating them as 
prospective drug leads.34,36,37 Currently fusafungine, an enniatin mixture, is marketed for 
topical use in upper respiratory tract infection for its antibiotic and anti-inflammatory 
properties.38  
 
Fig 1-10. The enniatins, fungal cyclohexadepsipeptides. 
Fungal cyclo-dipeptides in cancer chemotherapy 
Cyclo-dipeptides, referred to as diketopiperazines, are the smallest peptides composed of 
two amino acids joined in a head-to-tail fashion to form a characteristic heterocyclic ring. 
Their simple, rigid and chiral structure endows them with interesting biological activities, 
such as cytotoxic, anti-microbial and anti-inflammatory activities.39  
Since the concomitant isolation of phenylahistin (halimide) from cultures of a terrestrial 
and marine Aspergillus sp., by two independent work groups from opposite sides of the 
world, and the frantic quest for newer better anti-cancer analogues, employing the 
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natural scaffold of phenylahistin is ongoing.40,41 Phenylahistin features a phenylalanine 
and an isoprenylated dehydrohistidine moieties. With most of the anticancer drugs 
available to date being derived from natural products, nature’s contribution in treating 
and providing a better understanding of the cancer black box is highly appreciated.42 
Phenylahistin inhibited cell proliferation through a colchicine-like tubulin depolymerizing 
activity and showed cytotoxic activity towards several cancer cell lines.43 Plinabulin (NPI-
2358), a chemically modified analogue still retaining important structural features 
required for anticancer activity, i.e. a pseudo-tricyclic structure, an L-phenylalanine and a 
gem-dimethyl at position 5 of the imidazole,44 has completed phase 2 clinical studies as a 
vascular disrupting agent (VDA) in combination with docetaxel in patients with non-small 
cell lung cancer (NSCLC). VDA’s are a new class of anti-angiogenic agents targeting the 
present tumor vasculature, necessary for the growth and proliferation of solid tumors.45 
Plinabulin displayed notable antitumor activity with satisfactory safety and toxicity 
profiles and is to be moved to phase 3 testing.46 Profiting from emerging drug delivery 
technologies, an antibody drug conjugate of plinabulin is being developed for selective 
targeting of cancer cells.47 
 
Fig 1-11. Fungal diketopiperazines as anticancer drug leads. 
Another fungal diketopiperazine overarched by a disulfide bridge, which is gaining much 
attention, is the mycotoxin gliotoxin. It’s the prototype of the compound class 
epipolythiodioxopiperazine (ETP). Its biosynthesis from 2 amino acid building blocks, i.e. 
L-serine and L-phenylalanine has been extensively studied.48 Its toxicity is dependent on 
the sulfide bridge, which on the other hand is responsible for its potential therapeutic 
value. Gliotoxin targets hypoxia inducible factor-1 alpha (HIF-1α), which plays an 
important role in tumor progression and angiogenesis, and hence makes a promising 
anticancer drug scaffold.49   
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Fig 1-12. Gliotoxin biosynthesis, involving a series of enzyme-catalyzed steps converting phenylalanine and 
serine to gliotoxin (adopted from literature).
48 
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Fungal cyclic tetrapeptides as histone deacetylase (HDAC) inhibitors 
With the guidance of a trapoxin-based affinity compound, purification of histone 
deacetylase, an enzyme ubiquitously distributed and involved in several cellular 
mechanisms such as cell growth and development, was possible for the first time.50 
Epigenetic changes in the level of expression of histone deacetylase, results in several life 
threatening disorders, such as cardiovascular and neurological diseases, metabolic 
disorders and cancers. Histone deacetylase is regarded as the molecular target of histone 
deacetylase inhibitors and are thus recognized as a potential therapeutic domain for a 
wide range of prevalent diseases.51 Furthermore, cyclic peptides are an important class of 
HDAC inhibitors. 
Trapoxin, a hydrophobic cyclic tetrapeptide isolated from the fungus Helicoma ambiens, 
features a unique amino acid, 2-amino-8-oxo-9,10-epoxydecanoic acid (Aoe), which is 
responsible for its irreversible HDAC inhibitory activity. Other previously isolated fungal 
cyclic tetrapeptides with an epoxy-ketone group, such as HC toxin, chlamydocin, WF-3161 
and Cyl-2, similarly exhibited isoform selective inhibition of HDAC. A synthetic hybrid 
between the epoxy-ketone containing cyclic tetrapeptides and the hydroxamate class of 
HDAC inhibitors, resulted in a new class termed cyclic hydroxamic acid containing 
peptides (CHAP) with improved inhibitory activity and selectivity towards HDAC isoform 
classes.52 Apicidin isolated from Fusarium sp., although lacking a terminal α-keto epoxide, 
posses HDAC inhibitory activity. Thus Aoe is not essential for biological activity apart from 
exerting an irreversible inhibitory mechanism.50 The combined use of apicidin and 
docetaxol, a cytotoxic agent, was found to exhibit a synergistic anticancer effect with a 
reduction in adverse effects, thus discerning the beneficial effect of novel combination 
regimes for cancer treatment.53 Moreover, these non-ribosomally assembled cyclic 
tetrapeptides are used as conformational rigid scaffolds for the preparation of new HDAC 
inhibitors and simultaneously attain a deeper understanding of the pharmacophore 
elements essential for HDAC inhibitory activity.54 
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Fig 1-13. Fungal HDAC inhibitor peptides. 
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Ergopeptines/ Ergopeptides 
Ergopeptides are considered one of the oldest fungal metabolites. These are peptidic 
alkaloids isolated from the ergot fungus belonging to the genus Claviceps. They are 
composed of a tripeptide, modified into a bicyclic cyclo-lactam structure, linked to a 
tetracyclic ergoline ring. They have been used in folk medicine by midwives as an 
abortifacient, to induce labor and in treatment of post-partum hemorrhage. Their mode 
of action is generally realized from their agonist activity to several receptors as a result of 
their structural analogy to several neurotransmitters, e.g. serotonin, dopamine and 
epinephrine.55 Ergotamine, the major alkaloid produced by ergot, is still prescribed for 
acute migraines usually in combination with caffeine (Cafergot®). Bromocriptine 
(Parlodel®), a semi-synthetic derivative of the ergopeptide ergocriptine, is used in the 
treatment of hyperprolactinaemia and parkinson disease.56 In 2009, bromocriptine 
mesylate (Cycloset®) was approved by the FDA for treatment of type 2 diabetes.57  
 
Fig 1-14. Ergopeptides used as drugs. 
A unique feature of ergopeptine biosynthesis is their assembly by two NRPS subunits, a 
trimodular lysergylpeptidyl synthetase 1 (LPS1) and a monomodular lysergylpeptidyl 
synthetase 2 (LPS2). LPS2 is responsible for activation of D-lysergic acid, a modified 
tryptophan, which is sequentially elongated by LPS1 to form D-lysergyltripeptide. This is 
released as D-lysergyltripeptide lactam (L-ergopeptam), which then undergoes 
heterocyclization to give the ergopeptines.58 
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Fig 1-15. Ergopeptines biosynthesis. (adopted from literature).
58 
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Fungal Antimicrobial Peptides (AMP) 
With the upsurge of antibiotic resistant pathogens and its impact on the global public 
health, the relentless search for new antibiotics classes, that don’t readily develop 
resistance, is becoming no longer an extravagance.59,60 Antimicrobial peptides (AMP) 
preferably named host defense peptides (HDP), as their activities includes more than 
being antimicrobial, is an archaic part of the innate immune system of most multi-cellular 
organisms. Recently they have been the focus of research, initially for their novel anti-
infective potential, but also for a wide range of other clinical applications, such as anti-
inflammatory, anticancer, wound healing, vaccine adjuvants etc.61 
Defensins, the largest family of HDP, are gene-encoded cationic amphipathic cysteine-rich 
peptides stabilized through disulfide bridges.62 Plectasin, the first fungal defensin, was 
isolated from a black saprophytic ascomycete Pseudoplectania nigrella.63 It displayed 
potent antibacterial activity against Gram +ve bacteria, by inhibiting cell wall biosynthesis 
through complexing with bacterial cell wall precursor Lipid II.64 NZ-2114 a plectasin 
derivative with three mutational amino acids, showed superior activity against 
streptococci and staphylococci, including methicillin resistant 
Staphylococcus aureus (MRSA). Additionally, it demonstrated 
minimal cell toxicity with prolonged serum stability and in-vivo 
half-life, credited to its protease resistant disulfide-stabilized 
scaffold.65,66 NZ-2114 is currently undergoing preclinical 
development and may soon join other HDP entering clinical 
trials as a promising new generation of antibiotics.67 
 
a) GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCAKGGF--VCKCY 
    © Nature 2005 
Fig 1-16. a) Plectasin amino acid sequence, b) A single representative structure of plectasin in cartoon mode 
showing the proximity of disulphide bridges. Cystine bridges are highlighted in orange (adopted from 
literature).
63
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1.3 Peptides incorporating 3-(3-furyl)-alanine and their bioactivities 
Almost three decades ago, rhizonin A a heptapeptide mycotoxin, was isolated from 
Rhizopus microsporus, a fungus used to prepare fermented food such as tempeh, a 
popular vegetarian meat substitute.68 Two decades later, it was found to be originally 
produced by the bacterial endosymbiont Burkholderia sp.69 Rhizonin A is considered the 
major metabolite produced by the plant growth promoting rhizobacteria (PGPR) strain 
Burkholderia sp., enhancing seed germination and growth, and is to be explored for 
sustainable agriculture production.70  Interestingly, rhizonin A is the first naturally isolated 
peptide that contains 3-(3-furyl)-alanine, a non-proteinogenic amino acid rarely 
encountered in nature. Rhizonin A showed in-vitro hepatotoxicity, as well as in-vitro fat-
accumulation inhibitory activity against 3T3-L1 murine adipocytes.71 Synthetic 
replacement of 3-(3-furyl)-alanine with phenylalanine gave analogues with increased fat-
accumulation inhibitory activity and reduced cytotoxicity when compared to rhizonin A. 
Accordingly, cytotoxicity of rhizonin A could be ascribed to its 3-(3-furyl)-alanine content, 
which appears to be non-essential for the observed biological activity.72 This is in 
agreement with earlier studies focusing on synthetic heterocyclic analogues of 
phenylalanine, i.e. 3-(3-furyl)-alanine, exhibiting growth inhibitory activity in both 
bacteria and fungi, which was reversed by the addition of phenylalanine.73 
A cyclic pentapeptide bingchamide B, isolated from the soil-dwelling bacterial strain 
Streptomyces bingchenggensis, was also seen to incorporate this rare amino acid moiety. 
Bingchamide B showed in-vitro cytotoxic activity towards a human colon cancer cell line 
with an IC50 value of 18 µg ml
-1. This makes it an interesting scaffold for the development 
of antitumor agents.74  
Chemically synthesized L-3-(3-furyl) and L-3-(2-furyl)-alanine are used as an agrochemical 
fungicide, industrial microbiocide and wood preservative.75 So far, 3-(3-furyl)-alanine was 
never independently isolated from natural sources, apart from a carboxy derivative 
isolated from the fruiting bodies of the gilled mushrooms Phyllotopsis nidulans and 
Tricholomopsis rutilans.76,77   
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Little is known about the biosynthesis of this unusual amino acid, apart from being 
considered as a potential substrate of the NRPS machinery, known to incorporate such 
atypical building blocks.  
 
Fig 1-17. Peptides incorporating 3-(3-furyl)-alanine and a carboxy derivative of 3-(3-furyl)-alanine.
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2. Scope of the present study 
With the current trend towards peptide-based drugs, as observed in the increasing 
number of such compounds entering clinical trials annually,6 the search for new peptide 
scaffolds is ongoing. They are used for their diverse disease curing properties, as a 
platform for selective drug delivery or as a diagnostic tool to study biological process.78 
The design of peptides by fungal metabolism is unprecedented, which is notable from the 
growing number of publications focusing on fungal peptides. Fungi from diverse habitats, 
both terrestrial and marine, are investigated and yielded fascinating structural diversity 
and a wide spectrum of biological activity.18,79,80,81,82  
The scantly explored marine fungal strain Stachylidium sp. is elected in the present study 
for an in-depth investigation. Previous studies in our group demonstrated the metabolic 
capabilities of this strain in terms of unique metabolites. These belong to different 
compound classes (including peptides), with both interesting chemistry and biological 
activity.83,84,85 Furthermore, the Stachylidium sp. belongs to the phylum Ascomycota, the 
largest fungal phylum, whose members include the well known Penicillum and Aspergillus 
spp. extensively studied for their medicinal and disease causing properties. They are the 
most frequent producers of natural products, including the penicillin antibiotics and the 
cholesterol lower drug lovastatin. It is believed that the full biosynthetic potential of the 
Stachylidium sp. has not been totally brought to light. Much could be earned from 
studying this strain, in terms of unique chemistry, biosynthetic mechanisms employed 
and most important promising biological activity. 
Course of study 
The first part of the study has the aim to isolate and elucidate novel peptide scaffolds. 
With the help of chromatographic (VLC, HPLC) and spectroscopic (NMR, MS, UV, IR) 
techniques successful isolation and chemical characterization of novel metabolites is 
anticipated.  
The focus of the second part of the study is the intensive investigation of the biosynthetic 
origin of the isolated metabolites. Thus, classical isotope feeding experiments are 
planned, preceded by preliminary experiments to assist in setting up a successful feeding 
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protocol that would ensure maximal incorporation of fed precursors into the target 
metabolites.  
The third and last part is to evaluate the biological activity of the isolated metabolites 
with focus on their potential activity on the G protein-coupled galanin receptors. 
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3. Materials and Methods (General procedures)  
3.1 Fungal material 
The marine-derived fungus Stachylidium sp. was isolated in our lab from the sponge 
Callyspongia sp. cf. C. flammea, collected from the coral reef in Bare Island, New South 
Wales, Australia. The fungal strain was identified through the Belgian coordinated 
collections of microorganisms of the Catholic University of Louvain (BCCM/MUCL) by Dr. 
P. Massart and Dr. C. Decock. A fungal specimen is deposited at the Institute for 
Pharmaceutical Biology, University of Bonn, isolation number “293K04”, running number 
“220”. 
3.2 Cultivation and extraction 
Culture media 
Biomalt salt medium (BMS): 20 g L-1 biomalt extract, 15 g L-1 agar (for solid medium) and 1 
L ASW (artificial sea water): 0.10 g L-1 KBr, 23.48 g L-1 NaCl, 10.61 g L-1 MgClx6H2O, 1.47 g 
L-1 CaCl2x2H2O, 0.66 g L
-1 KCl, 0.04 g L-1 SrCl2x6H2O, 3.92 g L
-1 Na2SO4, 0.19 g L
-1 NaHCO3 
and 0.03 g L-1 H3BO3. 
Pre-cultures 
First pre-culture (solid): fungal strain was inoculated on BMS agar petri-dishes and 
incubated at 25°C for 4 weeks. 
Second pre-culture (liquid): from the first pre-culture, a seed inoculum was used to 
inoculate 1 L Erlenmeyer flasks (3 flasks) each containing 300 ml of liquid BMS media. 
Liquid pre-cultures were shaken at 121 rpm at 25°C for 10 days. 
Main culture 
From the previous liquid pre-culture, liquid seed inoculums were aseptically transferred 
to Fernbach flasks (5 ml for each flask) containing 250 ml BMS agar media and incubated 
at room temperature for 30 days.  
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Extraction 
At the end of the cultivation period (30 or 60 days), the homogenized fungal biomass and 
cultivation media were exhaustively extracted with ethyl acetate and concentrated under 
vacuum (using vacuum rotatory evaporator, 40°C) to yield the crude extract.  
3.3 Chromatography 
3.3.1 Thin Layer Chromatography (TLC) 
Standard chromatograms of extracts and fractions were developed on either TLC 
aluminum sheets silica gel 60 F254 (Merck) as stationary phase using a petroleum 
ether/acetone mixture in different concentrations or TLC aluminum sheets RP-18 F254 
(Merck) as stationary phase using a methanol/water mixture in different concentrations, 
both at room temperature under saturated conditions. Chromatogram detection was 
accomplished under UV light (λ 254 nm and 366 nm) and using vanillin-sulphuric acid 
spraying reagent (0.5 g vanillin dissolved in a mixture of 85 ml methanol, 10 ml acetic acid 
and 5 ml sulphuric acid, TLC plates heated at 100°C after spraying).  
3.3.2 Vacuum Liquid Chromatography (VLC) 
VLC was used for crude extract fractionation using Merck silica gel 60M (0.040-0.063 mm, 
230-400 mesh size) as sorbent. Standard glass columns (dimensions 10 x 2 cm) were wet 
packed and equilibrated under vacuum using petroleum ether. Two gradient solvent 
systems of increasing polarity were used for sample elution, either starting with 100% 
petroleum ether to 100% dichloromethane to 100% ethyl acetate to 100% acetone to 
100% methanol yielding 9 fractions or starting with 100% petroleum ether to 100% 
acetone to 100% methanol yielding 8 fractions. Fractions were collected and 
concentrated under vacuum (using vacuum rotatory evaporator, 40°C). 
3.3.3 High Performance Liquid Chromatography (HPLC) 
Preparative HPLC was performed on either (a) HPLC system composed of a Waters 515 
pump with a Knauer K-2300 differential refractometer, using a Knauer column (250 x 8 
mm, 5µm, Eurospher II-100 Si, flow rate 2 ml min-1) or (b) a Merck-Hitachi system 
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equipped with an L-6200A pump, an L-4500A photodiode array detector and a D-6000 
interface, using Macherey-Nagel columns (Nucleodur C18 EC Isis and Nucleodur C18 Sphinx  
RP each with 250 x 4.6 mm, 5µm, flow rate 1 ml min-1). 
3.4 Structure elucidation 
The chemical structures of the isolated compounds were established using one 
dimensional and two dimensional NMR techniques along with MS methods. Additional 
structural information was provided from optical rotation measurements, UV and IR 
spectroscopy. Database and literature search using MarinLit database®, AntiBase 
database® and Scifinder database® was performed to determine the novelty of the 
isolated compounds. 
3.4.1 NMR spectroscopy 
All NMR spectra were recorded in acetone-d6 or methanol-d4 referenced to residual 
solvent signals with resonances at δH/C 2.04/29.8 and δH/C 3.35/49.0 respectively, using 
either a Bruker Avance 300 DPX spectrometer operating at 300 MHz (1H) and 75 MHz 
(13C) or a Bruker Avance 500 DRX spectrometer operating at 500 MHz (1H) and 125 MHz 
(13C). Spectra were processed using Bruker 1D WIN-NMR, 2D WIN-NMR or XWIN-NMR 
version 2.6, 3.1 and 3.5 software. The following NMR experiments: 1H, 13C, DEPT 135, 1H-
1H COSY, 1H-13C direct correlation (HSQC), 1H-13C long range correlation (HMBC) and 1H-1H 
ROESY,  were performed for structural assignment. From DEPT experiments, multiplicity 
of carbons could be deduced. Incorporation of 13C-labeled precursors was evaluated using 
both 1H decoupled 13C NMR spectroscopy and inverse gated 1H decoupled 13C NMR 
spectroscopy. 
3.4.2 Mass Spectrometry (MS) 
HPLC-MS measurements were conducted by Ekaterina Eguereva (Institute for 
Pharmaceutical Biology, University of Bonn, Germany), employing an Agilent 1100 Series 
HPLC including DAD, with RP C18 column (Macherey Nagel Nucleodur 100, 125 x 2 mm, 
5µm) and a 2 mmol NH4Ac buffered methanol/water gradient elution system (flow rate 
0.25 ml min-1), starting from 10% to 100% MeOH over a 20 min period, then isocratic for 
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10 min. The HPLC system was coupled with an API 2000, Triple Quadrupole LC/MS/MS, 
Applied Biosystems/MDS Sciex and an ESI source. Samples were dissolved in MeOH (1 mg 
ml-1) prior to injection. 
HRESIMS measurements were conducted by C. Sondag (Department of Chemistry, 
University of Bonn, Germany) using a Bruker Daltonik micrOTOF-Q mass spectrometer 
with an ESI source. 
3.4.3 Optical rotation 
Optical rotations were measured on a Jasco DIP 140 polarimeter (1 dm, 1 cm3 cell) 
operating at wavelength λ=589 nm corresponding to the sodium D line at room 
temperature. Specific optical rotation [α]D
T was calculated pursuant to: 
100 × α 
[α]D
T= 
           c × l    
T: temperature [°C] 
D: sodium D line at λ=589 nm 
c: concentration [g/100 ml] 
l: cell length [dm]  
α: optical rotation 
Compounds were dissolved in methanol and the average optical rotation α was based on 
at least 10 measurements. 
3.4.4 UV measurements 
UV spectra were obtained using a Perkin Elmer Lambda 40 UV/Vis spectrometer with UV 
WinLab Version 2.80.03 software, using 1.0 cm quartz cell. The molar absorption 
coefficient ε was determined in accordance with the Lambert-Beer-Law: 
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A= ε × c × b         ε = A/(c × b) 
ε: molar absorption coefficient [L/mol×cm] 
A: absorption at peak maximum  
c: concentration [mol L-1] 
b: layer thickness of solution [cm] 
3.4.5 IR spectroscopy 
IR spectra were recorded as film using Perkin Elmer FT-IR Spectrum BX spectrometer, with 
Spectrum v3.01 software. 
3.4.6 Advanced Marfey’s method 
Peptide hydrolysis: Peptides (0.5 mg of each) were separately dissolved in 6 N HCl (0.5 
ml) and heated at 110°C for 16 hours in closed glass vials. After cooling, the solvent was 
removed using a nitrogen stream and redissolved in 50µl H2O.  
Derivatization: The peptide hydrolysate and 1 mg of each respective standard L- and D-
amino acid were resuspended in 50 µl H2O, and 100 µl of 1% (w/v) L-FDAA (in acetone) 
and 40 µl of 1 M NaHCO3 were added. The mixture was heated at 70°C for 40 minutes. 
After cooling to room temperature, the reaction was quenched by adding 20 µl of 2 N 
HCl, and solvents evaporated to dryness. 
Analysis: Samples were resuspended in MeOH (1 mg ml-1) for HPLC-MS analyses. 
Comparison of the retention times observed for the derivatized hydrolysates and the 
derivatized standards revealed the absolute configuration of the peptide residues. 
3.5 Biosynthetic studies 
3.5.1 Time-scale cultures 
The fungus was cultivated on BMS agar petri-dishes (incubated at room temperature) and 
liquid BMS Erlenmeyer flasks (shaken at 121 rpm and 25°C). Unlabeled compounds 
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(glycerol, phenylalanine and sodium acetate) were added as filter sterile aqueous 
solutions to some of the cultures (final concentration 1 mg ml-1). After defined time 
intervals (days 5, 9, 14, 20, 30 and 55), representative cultures were extracted with ethyl 
acetate and analyzed using HPLC-MS. Metabolites of interest were monitored at specific 
retention times.  
3.5.2 Precursor directed biosynthesis 
The fungus was cultivated on liquid (with shaking) and solid BMS media to which several 
precursors, including amino acids and halogenated precursors, were added as filter 
sterilized aqueous solutions (final conc. 1 mg ml-1) and cultivated for 15 and 30 days 
respectively, followed by extraction with ethyl acetate and analysis.  
3.5.3 Feeding experiment with [1-13C]phenylalanine 
The fungus was cultivated in four Fernbach flasks each containing 250 ml BMS agar media 
using a liquid seed inoculum from the second liquid fungal pre-culture (5 ml for each 
Fernbach flask). [1-13C]phenylalanine was added as filter sterilized aqueous solution twice 
on day 5 and day 10 (final conc. 1 mg ml-1). The flasks were incubated at room 
temperature for 30 days, followed by extraction with ethyl acetate and analysis.   
3.5.4 Feeding experiment with [U-13C]glycerol 
The fungus was cultivated in two Fernbach flasks each containing 250 ml BMS agar media 
using a liquid seed inoculum from the second liquid fungal pre-culture (5 ml for each 
Fernbach flask). [U-13C]glycerol was added as filter sterilized aqueous solution twice on 
day 5 and day 10 (final conc. 2 mg ml-1). The flasks were incubated at room temperature 
for 30 days, followed by extraction with ethyl acetate and analysis.   
3.5.5 Feeding experiment with [1-13C]glucose 
The fungus was cultivated in two Fernbach flasks each containing 250 ml BMS agar media 
using a liquid seed inoculum from the second liquid fungal pre-culture (5 ml for each 
Fernbach flask). [1-13C]glucose was added as filter sterilized aqueous solution twice on 
Materials and Methods 
30 
 
day 5 and day 10 (final conc. 2 mg ml-1). The flasks were incubated at room temperature 
for 30 days, followed by extraction with ethyl acetate and analysis.   
3.5.6 Feeding experiment with [1-13C]sodium acetate 
The fungus was cultivated in six Fernbach flasks each containing 250 ml BMS agar media 
using a liquid seed inoculum from the second liquid fungal pre-culture (5 ml for each 
Fernbach flask). [1-13C]sodium acetate was added as an autoclaved aqueous solution 
thrice on day 10, day 20 and day 30 (final conc. 2.5 mg ml-1). The flasks were incubated at 
room temperature for 60 days, followed by extraction with ethyl acetate and analysis.  
3.5.7 Feeding experiment with [Me-13C]methionine 
The fungus was cultivated in six Fernbach flasks each containing 250 ml BMS agar media 
using a liquid seed inoculum from the second liquid fungal pre-culture (5 ml for each 
Fernbach flask). [Me-13C]methionine was added as filter sterilized aqueous solution thrice 
on day 10, day 20 and day 30 (final conc. 1.3 mg ml-1). The flasks were incubated at room 
temperature for 60 days, followed by extraction with ethyl acetate and analysis.  
3.5.8 Feeding experiment with [1,7-13C]shikimic acid 
The fungus was cultivated in a petri-dish containing 10 ml BMS agar media using a liquid 
seed inoculum (0.5 ml) from the second liquid fungal pre-culture. [1,7-13C]shikimic acid 
was added as filter sterilized aqueous solution twice on day 5 and day 10 (final conc. 1 mg 
ml-1). The petri-dish was incubated at room temperature for 30 days, followed by 
extraction with ethyl acetate and analysis. 
3.6 Biological testing 
3.6.1 Agar diffusion assays 
Antimicrobial tests of isolated compounds were performed by Edith Neu (Institute for 
Pharmaceutical Biology, University of Bonn) following the method described by Schulz et 
al.86,87 The bacteria Bacillus megaterium and Escherichia coli were used as representatives 
for gram positive and gram negative bacteria. Microbotryum violaceum (Ustomycetes), 
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Eurotium rubrum (formerly E. repens) (Ascomycetes), and Mycotypha microspora 
(Zygomycetes) were used as fungal test organisms.  
Pure compounds were dissolved in acetone or methanol to give a concentration of 1 mg 
ml-1 per test sample. 50 µl (equivalent to 50 µg) of each solution were pipetted onto 
sterile filter disks (diameter: 9 mm, Schleicher & Schuell 2668), which was then placed 
onto the appropriate agar medium and sprayed with a suspension of the test organism. 
Growth media, preparation of spraying suspensions and conditions of incubation were 
carried out according to Schulz et al.87 For tested samples, a growth inhibition zone ≥ 3 
mm and/or a complete inhibition ≥ 1 mm, measured from the edge of the filter disk, were 
regarded as a positive result. Growth inhibition was defined as follows: growth of the 
appropriate test organism was significantly inhibited compared to a negative control; 
total inhibition: no growth at all in the appropriate zone. Benzyl penicillin (1 mg ml-1 
MeOH), streptomycin (1 mg ml-1 MeOH) and miconazole (0.5 mg ml-1 DCM) were used as 
positive controls. 
3.6.2 Label-free dynamic mass redistribution (DMR) assay for galanin receptors - 
HEK293 cell lines 
Label-free dynamic mass redistribution assays were performed by working group Kostenis 
(Institute for Pharmaceutical Biology, University of Bonn), as described previously in 
detail, recorded on the EnSpire® multimode plate reader (Perkin Elmer, Hamburg, 
Germany) at 37oC.88,89 
Native and recombinant human embryonic kidney (HEK293) cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal calf 
serum (FCS), penicillin (100 U ml-1) and streptomycin (100 µg ml-1). For recombinant 
HEK293 cell lines harboring human galanin receptor type1 (GalR1), the medium was 
supplemented with G418 (450 µg ml-1) (InvivoGen). cDNA coding for this receptor cloned 
into pcDNA3.1+ (Invitrogen) at EcoRI (5’) and XhoI (3’) was purchased from UMR cDNA 
Resource center, University of Missouri-Rolla, Rolla, USA. Stable single cell clone-derived 
cell lines were generated by Ca2+ phosphate co-precipitation in conjunction with clonal 
selection using G418 as described previously.90 All cells were cultivated with 5% CO2 at 
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37oC in a humidified atmosphere. For signal pathway inhibition, cells were incubated for 
16 h with 200 ng ml-1 of pertussis toxin (PTX). 
3.7 Chemicals and other materials 
Chemicals were supplied by Merck (Germany), Fluka (Switzerland), Roth (Germany) and 
Sigma-Aldrich (Germany). Stable isotope labeled compounds [1-13C]phenylalanine, [U-
13C]glycerol, [1-13C]glucose, [1-13C]sodium acetate and [Me-13C]methionine were obtained 
from Cambridge Isotope Laboratories. [1,7-13C]shikimic acid was kindly provided by Prof. 
Dr. Taifo Mahmud from the Oregon State University, USA. All precursors were filter 
sterilized using Millipore filters (pore size 0.20 µm) or autoclaved (for [1-13C]sodium 
acetate). Deuterated NMR solvents were supplied from Deutero GmbH (Germany).  
Solvents used where either distilled before use, of HPLC grade or LC/MS grade. 
Deionized water used was obtained from a Milli-Q-system. 
3.7.1 Materials and reagents for cell culture and molecular biology 
Tissue culture media and reagents were purchased from Invitrogen. Pertussis toxin (PTX) 
was from BIOTREND Chemikalien GmbH, restriction endonucleases and modifying 
enzymes were from New England Biolabs. All other laboratory reagents for cell culture, 
molecular biology and DMR assays were obtained from Sigma-Aldrich unless otherwise 
specified. 
3.7.2 Synthesis of 2-chloro-protocatechuic acid  
Demethylation of commercially available 2-chloro-3,4-dimethoxybenzoic acid to give 2-
chloro-protocatechuic acid was conducted under supervision of Dr. Nader Boshta, 
Pharmaceutical Chemistry I, University of Bonn. Demethylation was carried out using 
boron tribromide in dichloromethane (molar ratio of 2-chloro-3,4-dimethoxybenzoic acid 
to BBr3 1:2) for 24 h. The reaction mixture was then neutralized with NaHCO3 until 
evolution of CO2 stopped (pH 7.0). The mixture was then extracted three times with 
dichloromethane, washed with water and dried over MgSO4.
91 
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4. Results 
4.1 Isolation of novel cyclic peptides from Stachylidium sp.  
A 3 liter culture of Stachylidium sp. on biomalt agar medium supplemented with sea salt 
was cultivated for 30 days at room temperature (see 3.2). Fungal biomass and media 
were homogenized with an Ultra-Turrax followed by exhaustive extraction with ethyl 
acetate to yield 600 mg of crude extract. This was further subjected to VLC fractionation 
on silica open columns using a gradient solvent system of increasing polarity (see 3.3.2), 
starting with 100% petroleum ether to 100% dichloromethane to 100% ethyl acetate to 
100% acetone to 100% methanol, yielding 9 fractions. Cyclic tetrapeptides (peptides 1-7) 
were isolated from VLC fraction 4, by NP-HPLC fractionation using petroleum 
ether/acetone (3:1) and RP-HPLC using methanol/water systems. Diketopiperazines 
(peptides 8 and 9) were isolated from VLC fractions 6 and 7, by NP-HPLC fractionation 
using petroleum ether/acetone (2:3) and RP-HPLC using a methanol/water system (Fig 4-
1). 
 
Fig 4-1. Isolation scheme for cyclic peptides (1-9) from a 30 day Stachylidium sp. culture on biomalt salt agar 
medium. Experimental details are described in section 3.3. 
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4.2 Structure elucidation of isolated novel cyclic peptides  
1H and 13C NMR spectra of the isolated compounds 1-7 exhibited typical signals indicative 
of a tetrapeptide molecule. The 1H NMR spectra showed four signals between δ 4 - 5 
characteristic for the α protons of four amino acid residues, two methyl singlets at around 
δ 2.8, indicative of N-methyl protons, and two broad doublets at around δ 7.9 
characteristic for amide protons. Diastereotopic β proton resonances were observed 
between δ 2.5 - 3.7. The region between δ 7.0 - 7.5 showed overlapping resonances due 
to aromatic ring protons pointing to the inclusion of aromatic amino acid residues. In 
addition, the 13C NMR spectra displayed four down-field signals between δ 170 and δ 173, 
attributable to amide carbonyls, as well as signals between δ 50 - 70, where peptidic α-
carbons normally appear. Presence of 2 amide protons and N-methyl singlets in the 
spectra implied a cyclic structure for the tetrapeptides.  
Four of the isolated peptides, i.e. peptides 1, 5, 6 and 7, displayed doubling of the signals 
in both 1H and 13C NMR spectra. A first hint pointed to the likely-hood of the presence of 
conformational isomers, frequently seen in peptides and justified by the conformational 
flexibility of the constituent amino acid residues.92 NMR measurements at elevated 
temperatures or using different solvents did not result in improvements of NMR 
resolution as normally expected with peptide conformers.93 From the detailed 
investigation of the 2D-NMR spectroscopic data we could conclude that these peptides 
are isolated as a mixture of co-eluting positional isomers with similar chromatographic 
properties and differing only in the connectivities of the constituent amino acid residues. 
Trials to purify them further using different HPLC stationary phases and mobile phase 
systems were unsuccessful, especially due to the small amounts isolated, and in several 
instances separation of peptide isomers using liquid chromatography was most 
challenging.94  
HRESIMS of peptide 1 and 1’ showed an ion peak at m/z 547.2902 [M+Na]+ and was 
assigned a molecular formula of C29H39N4O5  indicating 12 degrees of unsaturation. The 
1H 
NMR and 13C NMR spectra revealed doubling of signals suggesting the presence of 
inseparable isomers (Fig S3 and S4). The 1H NMR spectrum displayed eight α proton 
signals between δ 4 – 5, two splitted singlets at δ 2.7 and δ 2.8, indicated the presence of 
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N-methyl protons, and two doublets at δ 7.84 and δ 7.92, characteristic for amide 
protons. The 13C NMR spectrum displayed six carbonyl signals, four resonances at δ 171.8, 
δ 172.2, δ 172.5 and δ 172.9, and two signals at δ 170.5, and δ 170.9 with double the 
intensity, along with four splitted α carbon signals at δ 49.0, δ 56.0, δ 62.0 and δ 63.0. 
This pointed to the preliminary assignment of a mixture of two closely related cyclic 
tetrapeptide isomers. Proton and carbon resonances in the aromatic region were 
suggestive of two distinct aromatic moieties, of which one incorporates an oxygen atom 
(as indicated from the molecular formula), anticipated to be a furyl moiety, while the 
remaining resonances in the aromatic region where indicative of a phenyl moiety. The 
structure of the remaining amino acid residues were assigned as valine and leucine. 
Comprehensive analysis of the 2D NMR spectroscopic data revealed the structures and 
sequence of four heterogeneous amino acid residues: N-MeFurAla, Leu, N-MePhe and Val 
(Table 4-1).  
 
For peptide 1, spin systems in COSY and HMBC were assigned to valine, as correlations 
ranging from CH3-28 and CH3-29 to βCH-27 and αCH-26, and correlations of βCH-27 and 
αCH-26 with qC-25 were observed. The valine unit was not methylated as COSY 
correlations were observed between αH-26 (δH 4.26) and NH-26 (δH 7.84). Another 
subunit was allocated as leucine determined from the COSY spin system linking the two 
methyl groups, CH3-13 and CH3-14, to NH-10 (δH 7.92) through γH-12, βH2-11 and αH-10. 
Further HMBC correlations of βCH2-11 and αCH-10 to the qC-9 finalized the assignment of 
a non-methylated leucine. Characteristic carbon resonances at δ 144.5, δ 141.1, δ 110.9 
and δ 122.0 along with their relevant proton resonances at δ 7.55, δ 7.46 and δ 6.41 
established a furyl moiety. Two of the three sp2 methine protons of the furyl moiety, i.e 
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H-6 (δH 7.55) and H-7 (δH 7.46), were shifted downfield due to the deshielding effect of a 
common adjacent oxygen. CH-5 and CH-7 are both connected to the quaternary carbon, 
qC-4 (δc 122.0), deduced from the HMBC correlations of H-5 and H-7 to qC-4, hence 
closing the furyl ring. Supplementary COSY and HMBC correlations of CH-5 and CH-7 to 
βCH2-3, and between βCH2-3 and αCH-2, along with that between the carbonyl qC-1 (δC 
170.9) and the NCH3-8 (δH 2.80) ascribed this residue as N-methyl-3-(3-furyl)-alanine. 
Residual resonances were assigned to the second aromatic and last residue. The COSY 
spectrum revealed correlations of five aromatic methine protons, which were assigned a 
spin system H-19, H-20, H-21, H-22 and H-23. HMBC correlations between H-19 and H-23 
to CH2-17 (δc 34.7), H-20 and H-22 to qC-18 (δc 139.0), of H2-17 and H-16 to the carbonyl 
qC-15 (δC 170.5), and of αCH-16 to NCH3-24 (δH 2.75) concluded the last residue as an N-
methyl-phenylalanine. The sequential relationship of the four amino acid residues was 
deduced from HMBC correlations of the α-protons of the amino acid residues and the 
carbonyl carbon of the adjacent amino acid, thus αCH-2 (NMeFurAla) to qC-9 (Leu), αCH-
10 (Leu) to qC-15 (NMePhe), αCH-16 (NMePhe) to qC-25 (Val) and αCH-26 (Val) to qC-1 
(NMeFurAla). This was fortified with HMBC correlations of the N-methyl substituents with 
the adjacent carbonyl carbons and α protons, that is NCH3-8 (δH 2.80) to qC-9 (δc 172.9) 
and αCH-2 (δH 4.42), NCH3-24 (δH 2.75) to qC-25 (δc 171.8) and αCH-16 (δH 4.51). Thus the 
final peptide sequence was assigned as cyclo-[N-methyl-3-(3-furyl)-alanyl, leucyl, N-
methyl-phenylalanyl, valinyl]. 
For peptide 1’, the same amino acid residues were confirmed, differing only in their 
connectivity. This was deduced from HMBC correlations between amide protons to 
carbonyl carbons of the adjacent amino acids, i.e. NH-10 (Val) to qC-14 (NMePhe) and 
from NH-25 (Leu) to qC-1 (NMeFurAla), as well as HMBC correlations between the N-
methyl and the adjacent carbonyl carbons and α-protons, i.e. from NCH3-8 (NMeFurAla) 
to qC-9 (Val) and αCH-2 (NMeFurAla), and from NCH3-23 (NMePhe) to qC-24 (Leu) and 
αCH-15 (NMePhe). Thus the final peptide sequence was assigned as cyclo-[N-methyl-3-(3-
furyl)-alanyl, valinyl, N-methyl-phenylalanyl, leucyl].    
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Table 4-1. 1D NMR spectroscopic data for peptide 1 and 1’. 
Peptide 1: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-leucyl, N-methyl-(L)-phenylalanyl, (L)-valinyl] 
Peptide 1’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, N-methyl-(L)-phenylalanyl, (L)-leucyl] 
Peptide 1 Peptide 1‘ 
Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
N-Me-L-FurAla 1 170.90, qC - N-Me-L-FurAla 1 170.50, qC - 
 2   62.80, CH 4.42, dd (3.3,11.7)  2   62.70, CH 4.34, dd (3.3, 11.7) 
 3   24.50, CH2 a: 2.97, dd (11.0, 15.0)  3   24.50, CH2 a: 2.96, dd (11.0, 15.0) 
   b: 3.42, dd (3.3, 15.0)    b: 3.41, dd (3.3, 15.0) 
 4 122.00, qC -  4 122.00, qC - 
 5 110.90, CH 6.41, br s  5 110.90, CH 6.41, br s 
 6 144.50, CH 7.55, br s  6 144.50, CH 7.55, br s 
 7 141.10, CH 7.46, br s  7 141.10, CH 7.46, br s 
 8   30.70, CH3 2.80, s  8   30.40, CH3 2.76, s 
 N    N   
L-Leu 9 172.90, qC - L-Val 9 172.20, qC - 
 10   49.30, CH 4.71, m  10   56.30, CH 4.39, t (8.8) 
 11   42.00, CH2 a:1.33, m  11   30.20, CH 2.15, m 
   b:1.67, m  12   20.80, CH3 0.87, d (6.6) 
 12   25.00, CH 1.45, m  13   18.40, CH3 0.90, d (6.6) 
 13   22.50, CH3 0.83, d (6.6)  NH-10 - 7.84, d (9.5) 
 14   23.20, CH3 0.78, d (6.6) N-Me-L-Phe 14 170.90, qC - 
 NH-10  - 7.92, d (9.5)  15   63.80, CH 4.59, br d (11.7) 
N-Me-L-Phe 15 170.50, qC -  16   34.70, CH2 a: 3.01, m 
 16   63.50, CH 4.51, br d (11.7)    b: 3.69, m 
 17   34.70, CH2 a: 3.00, m  17 139.00, qC - 
   b: 3.67, m  18 129.20, CH 7.31, m 
 18 139.00, qC -  19 129.50, CH 7.31, m 
 19 129.20, CH 7.31, m  20 127.50, CH 7.24, m 
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Peptide 1 Peptide 1‘ 
Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
 20 129.50, CH 7.31, m  21 129.50, CH 7.31, m 
 21 127.50, CH 7.24, m  22 129.20, CH 7.31, m 
 22 129.50, CH 7.31, m  23   30.70, CH3 2.81, s 
 23 129.20, CH 7.31, m  N   
 24   30.40, CH3 2.75, s L-Leu 24 172.50, qC - 
 N    25   49.10, CH 4.60, m 
L-Val 25 171.80, qC -  26   41.90, CH2 a:1.23, m 
 26   56.20, CH 4.26, t (8.8)    b:1.60, m 
 27   30.00, CH 2.03, m  27   25.00, CH 1.58, m 
 28   20.70, CH3 0.72, d (6.6)  28   22.50, CH3 0.91, d (6.6) 
 29   18.40, CH3 0.83, d (6.6)  29   23.30, CH3 0.87, d (6.6) 
 NH-26 - 7.84, d (9.5)  NH-25 - 7.92, d (9.5) 
a
 CD3COCD3, 300/75.5 MHz. 
b
 Assignments are based on extensive 1D and 2D NMR experiments (HMBC, HSQC, COSY).  
c
 Implied multiplicities determined by DEPT.  
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Peptide 2 was assigned a molecular formula of C32H37N4O5 
using HRESIMS, indicating 16 degrees of unsaturation. The 
13C NMR and DEPT135 spectra revealed 32 resonances, 
resulting from four methyls, three methylenes, five sp3 
methines, 13 sp2 methines and seven quaternary carbons. 
The 1H NMR spectrum (Fig S5) displayed four α proton 
signals at δ 4.26, δ 4.50, δ 4.55 and δ 4.78. Two singlets at 
δ 2.72 and δ 2.79 indicated the presence of two N-methyl 
protons and two doublets at δ 7.79 and δ 7.93 are characteristic for amide protons. The 
13C NMR spectrum (Fig S6) displayed four carbonyl signals at δ 170.4, δ 171.0, δ 171.8 and 
δ 172.2, along with four α carbon signals at δ 51.4, δ 56.2, δ 63.5 and δ 63.6, all resulting 
in the preliminary assignment of a peptide-like molecule, composed of four amino acid 
residues, two of which are N-methylated. Comprehensive analysis of the 2D NMR 
spectroscopic data revealed the sequence and structures of the four amino acid residues 
of peptide 2 as NMePhe, FurAla, NMePhe and Val (Table 4-2). COSY revealed correlations 
of two closely related spin systems, each consisting of five aromatic methine protons, one 
reaching from H-5 through to H-9, and a second from H-22 through to H-26. HMBC 
correlations assigned quaternary carbons qC-4 (δC 138.93) to the first and qC-21 (δC 
138.90) to the second aromatic ring respectively. The first aromatic ring displayed HMBC 
correlations between H-5 (δH 7.27), and H-9 (δH 7.27), to CH2-3 (δc 35.0), which showed a 
strong correlation in both COSY and HMBC to αCH-2 (δH/δC 4.55/63.6). Both CH2-3 and 
αCH-2 displayed HMBC correlations to the quaternary carbonyl qC-1 (δC 171.0), hence 
concluding the first aromatic amino acid as phenylalanine (Phe A). The second aromatic 
ring showed similar correlations and hence concluded the second aromatic amino acid 
also to be phenylalanine (Phe B). HMBC correlations from CH3-31 and CH3-32 to βCH-30 
and αCH-29, and from H-30 (δH 2.04) and H-29 (δc 4.26), to the quaternary carbonyl 
carbon qC-28 (δc 171.8), along with COSY correlations of H-29 and NH-29 (δH 7.79), lead 
to the identification of a valine amino acid unit which was not N-methylated. The last 
residue displayed carbon resonances characteristic for a 3-substituted furyl moiety, i.e. δ 
143.2, δ 141.1, δ 121.8 and δ 112.7. This is confirmed with HMBC correlations from sp2 
methines H-15 (δH 6.20), and H-17 (δH 7.14), to the quaternary furyl carbon qC-14 (δC 
121.8). COSY evidenced a spin system from αH-12 (δH 4.78), to NH-12 (δ 7.93). The αCH-
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12 (δC 51.35) carbon resonance was shifted upfield indicating that this unit was not N-
methylated. HMBC correlations of αCH-12 and βCH-13 with the carbonyl carbon qC-11 (δC 
172.2), finalized the assignment of the last residue as 3-(3-furyl)-alanine. The sequential 
relationship of the four amino acid residues was deduced from HMBC correlations of the 
α-protons of the amino acid residues and the carbonyl carbon of the adjacent amino acid, 
i.e. αCH-2 (Phe A) to qC-11 (FurAla), αCH-12 (FurAla) to qC-18 (Phe B), αCH-19 (PheB) to 
qC-28 (Val) and αCH-29 (Val) to qC-1 (Phe A). The N-methyl substituents were positioned 
on the relevant amino acid residues Phe A and Phe B, based on HMBC correlations with 
their adjacent carbonyl carbons and α protons, that is NCH3-10 to qC-11 and αCH-2, 
NCH3-27 to qC-28 and αCH-19. This supplemented the peptide sequence, as cyclo-(N-
methyl-phenylalanyl, furylalanyl, N-methyl-phenylalanyl, valinyl). 
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Table 4-2. 1D and 2D NMR spectroscopic data for peptide 2, (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-
furylalanyl, N-methyl-(L)-phenylalanyl, (L)-valinyl]. 
Amino acid position δC, mult.
a, b, e
 δH
a, b
 (J in Hz) COSY
a, c
 HMBC
a, d
 
N-Me-L-Phe  1  171.00, qC -   
 2    63.64, CH 4.55, dd (3.3, 11.7) 3a, 3b 1, 3, 4, 10, 11 
 3    35.00, CH2 a: 3.67, dd (3.3, 15.0) 2, 3b 2, 4, 5, 9 
   b: 3.02, dd (11.7, 15.0) 2, 3a 1, 2, 4, 5, 10 
 4  138.93, qC -   
 5  129.10, CH 7.27, m 6 3, 4, 6, 7 
 6  129.50, CH 7.30, m 5, 7 5, 7, 8 
 7  127.50, CH 7.23, m 6, 8 5, 6, 8, 9 
 8  129.50, CH 7.30, m 7, 9 6, 7, 9 
 9  129.10, CH 7.27, m 8 3, 4, 7, 8 
 10    30.90, CH3 2.79, s  2, 11 
  N       
L-FurAla 11   172.20, qC -   
 12 51.35, CH 4.78, dt (9.5, 6.6) 13a, 13b, NH-12 11, 13, 14, 18 
 13 28.00, CH2 a: 2.52, dd (6.6, 15.0) 12, 13b, 17 11, 12, 14, 15, 17 
   b: 2.90, dd (6.6, 15.0) 12, 13a, 17  
 14 121.80, qC -   
 15 112.70, CH 6.20, br s 16, 17 13, 14, 16, 17 
 16 143.20, CH 7.38, t (1.8)  15, 17  15, 17 
 17 141.10, CH 7.14, br s  13, 15, 16 13, 14, 15, 16 
  NH-12  - 7.93, d (9.5) 12  
N-Me-L-Phe 18  170.40, qC -   
 19    63.50, CH 4.50, dd (3.3, 11.7) 20a, 20b 18, 20, 21, 27, 28 
 20    34.70, CH2 a: 3.61, dd (3.3, 15.0) 19, 20b 18, 21 
   b: 2.92, dd (11.7, 15.0) 19, 20a  
 21  138.90, qC -   
 22  129.20, CH 7.27, m 23 20, 21, 23, 24 
 23  129.50, CH 7.30, m 22, 24 21, 22, 24, 25 
 24  127.50, CH 7.23, m 23, 25 22, 23, 25, 26 
 25  129.50, CH 7.30, m 24, 26 20, 21, 23, 24, 26 
 26  129.20, CH 7.27, m 25 19, 20, 21, 22, 25 
 27    30.50, CH3 2.72, s  19, 28 
  N       
L-Val 28   171.80, qC -   
 29 56.20, CH 4.26, dd (7.7, 9.2) 30, NH-29 1, 28, 30, 31, 32 
 30 30.40, CH 2.04, m 29, 31, 32 28, 29, 31, 32 
 31 20.70, CH3 0.68, d (6.6) 30 29, 30, 32 
 32 18.40, CH3 0.82, d (7.0) 30 29, 30, 31 
  NH-29  - 7.79, d (9.2) 29  
a 
CD3COCD3, 300/75.5 MHz. 
b 
Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). 
c
 Numbers refer to proton resonances. 
d
 Numbers refer to carbon resonances. 
e
 Implied 
multiplicities determined by DEPT.  
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Peptide 3 was assigned a molecular formula of C34H40N4O4 using 
HRESIMS, indicating 17 degrees of unsaturation. The 13C NMR 
and DEPT135 spectra revealed 34 resonances, resulting from four 
methyls, three methylenes, five sp3 methines, 15 sp2 methines 
and seven quaternary carbons. The molecular formula of peptide 
3 had one oxygen atom less than peptide 2, suggesting a closely 
related structure in which the furylalanine moiety is replaced by 
a more hydrophobic residue as deduced from NP-HPLC. Signals similar to those of peptide 
2 were observed in the 1H and 13C NMR spectra (Fig S7 and S8), due to the presence of a 
valine and two N-methyl-phenylalanine moieties. Characteristic signals for the 
furylalanine moiety were not observed, instead overlapping resonances were observed in 
the aromatic region and these were assigned to the aromatic spin systems H-15, H-16, H-
17, H-18 and H-19. They displayed HMBC correlations between H-15 (δH 7.07), and H-19 
(δH 7.07), to βCH2-13 (δC 38.4), which showed a strong correlation to αCH-12 (δH/δC 
4.91/52.1). Both αCH-12 and βCH2-13 displayed HMBC correlations to the quaternary qC-
14 (δC 139.0) and carbonyl qC-11 (δC 172.1), thus concluding an additional phenylalanine 
residue. This is consistent with our earlier speculations concerning the replacement of the 
furylalanine residue with an aromatic and probably more hydrophobic residue in this case 
phenylalanine. The HRESIMS spectrum showed an ion peak at m/z 569.3119 [M+H]+, 
which through comparison of spectroscopic data with literature values revealed this 
peptide as cyclo-(N-methyl-phenylalanyl, phenylalanyl, N-methyl-phenylalanyl, valinyl) 
(Table 4-3). This peptide was reported from an entomopathogenic fungus Hirsutella sp. 
and was named hirsutide sequent to the producing organism.95 
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Table 4-3. 1D and 2D NMR spectroscopic data for peptide 3,  (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-
phenylalanyl, N-methyl-(L)-phenylalanyl, (L)-valinyl]. 
Amino acid Position δC, mult.
a, b, e
 δH
a, b
 (J in Hz) COSY
a, c
 HMBC
a, d
 
N-Me-L-Phe  1 171.00, qC -   
 2    63.58, CH 4.56, dd (3.3, 11.7) 3 1, 3, 4, 10 
 3    34.98, CH2 a: 3.66, dd (3.3, 15.0) 2 2, 4, 5, 9 
   b: 3.01, dd (11.7, 15.0)   
 4  139.00, qC -   
 5  129.00, CH 7.24, m 6, 7 3, 4, 7, 9 
 6  129.50, CH 7.30, m 5, 7 5, 7, 8, 9 
 7  127.50, CH 7.24, m 6, 8 5, 6, 8, 9 
 8  129.50, CH 7.30, m 7, 9 4, 7, 9 
 9  129.00, CH 7.24, m 8 3, 4, 7, 8 
 10    31.25, CH3 2.77, s 2, 3 2, 11 
  N       
L-Phe  11 172.10,qC -   
 12   52.10,CH 4.91, dt (9.5, 7.0) 13, NH-12 11, 13, 14 
 13   38.40, CH2 a: 2.66, dd (7.0, 13.9) 12 11, 12, 14, 15, 19 
   b:3.11, dd (7.0, 13.9)   
 14 139.00, qC -   
 15 130.20, CH 7.07, d (7.0) 16 13, 14, 16, 17 
 16 128.80, CH 7.22, m 15, 17 14, 15, 18 
 17 126.80, CH 7.16, m 16, 18 14, 15, 16, 18, 19 
 18 128.80, CH 7.22, m 17, 19 14, 16, 17, 19 
 19 130.20, CH 7.07, d (7.0) 18 13, 14, 17, 18 
 NH-12 - 7.97, d (9.5) 12  
N-Me-L-Phe  20  170.10, qC -   
 21    63.40, CH 4.46, dd (3.3, 11.7) 22 20, 22, 23, 29 
 22    34.68, CH2 a: 3.52, br d (15.0) 21 21, 23, 24, 28, 29 
   b: 2.80, dd (11.7, 15.0)   
 23  139.00, qC -  21, 22, 24, 25 
 24  129.00, CH 7.24, m 22a, 25 22, 23, 25, 26 
 25  129.50, CH 7.30, m 24, 26 23, 24, 26, 27 
 26  127.47, CH 7.24, m 25, 27 24, 25, 27, 28 
 27  129.50, CH 7.30, m 26, 28 23, 25, 26, 28 
 28  129.00, CH 7.24, m 22a, 27 21, 22, 26, 27 
 29    31.07, CH3 2.72, s  21, 30 
  N         
L-Val 30   171.80, qC -   
 31     56.20, CH 4.25, br t (8.05) 32, NH-31 30, 32, 33, 34 
 32     30.50, CH 2.04, m 31, 33, 34 31, 33, 34 
 33     20.70, CH3 0.70, d (6.6) 32, 34 31, 32, 34 
 34     18.50, CH3 0.82, d (6.6) 32, 34 31, 32, 33 
  NH-31   - 7.8, d (9.5) 31  
a 
CD3COCD3, 300/75.5 MHz. 
b 
Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). 
c
 Numbers refer to proton resonances. 
d
 Numbers refer to carbon resonances. 
e
 Implied 
multiplicities determined by DEPT.  
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Peptides 4 and peptide 5 and 5’ were isolated from the same NP-HPLC fraction, showed 
very close HPLC retention times and an ion peak at m/z of 571.2532 [M+Na]+ and 
571.2526 [M+Na]+ using HRESIMS for peptide 4 and peptide 5 and 5’, respectively. They 
were assigned a molecular formula of C30H35N4O6, indicating 15 degrees of unsaturation. 
They displayed differing 1H and 13C NMR spectra which suggested two closely related 
compounds with probably the same amino acid composition but differing in their 
connectivity.  
The 13C NMR and DEPT135 spectra of peptide 4 
revealed 30 resonances, resulting from four methyls, 
three methylenes, five sp3 methines, 11 sp2 methines 
and seven quaternary carbons. 1H and 13C NMR spectra 
(Fig S9 and S10) displayed characteristic proton and 
carbon resonances for two magnetically equivalent 3-
(3-furyl)-alanine moieties, which were N-methylated. 
The remaining proton and carbon resonances in the aromatic region where indicative of a 
phenylalanine residue. COSY correlations between NH-23 (δH 7.93) and αH-23 (δH 4.96) 
indicated that the phenylalanine residue was not N-methylated. The last residue was 
ascribed as valine based on COSY and HMBC correlations. COSY correlations between NH-
10 (δH 7.77) and αH-10 (δH 4.36) indicated that the valine residue was not N-methylated. 
The sequential relationship of the four amino acid residues was deduced from HMBC 
correlations of the α-protons of the amino acid residues and the carbonyl carbon of the 
adjacent amino acid, i.e. αCH-2 (FurAla A) to qC-9 (Val), αCH-10 (Val) to qC-14 (FurAla B), 
αCH-15 (FurAla B) to qC-22 (Phe) and αCH-23 (Phe) to qC-1 (FurAla A) and was 
supplemented with HMBC correlations of the N-methyl substituents. Thus peptide 4 was 
assigned as cyclo-[N-methyl-3-(3-furyl)-alanyl, valinyl, N-methyl-3-(3-furyl)-alanyl, 
phenylalanyl] (Table 4-4). 
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Table 4-4. 1D and 2D NMR spectroscopic data for peptide 4, (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-
valinyl, (N-methyl-(L)-3-(3-furyl)-alanyl), (L)-phenylalanyl]. 
Amino acid Position   δC, mult.
a, b, e
 δH
a, b
 (J in Hz) COSY
a, c
 HMBC
a, d
 
N-Me- 1   169.80, qC -   
L-FurAla  2 62.50, CH 4.25, dd (3.3, 11.7) 3a, 3b 1, 3, 4, 8, 9 
 3 24.30, CH2 a: 2.73, m 2, 3b 1, 2, 4, 5, 7 
   b: 3.22, dd (3.3, 15.6)  2, 3a, 7  
 4   122.00, qC -   
 5   110.95, CH 6.30, dd (0.9, 1.7) 6, 7 3a, 4,  6, 7 
 6   144.40, CH 7.50, t (1.7) 5 4, 5, 7 
 7   140.90, CH 7.37,  br s 5, 3b 3a, 4,  5, 6 
 8 30.50, CH3 2.71, s   2, 9 
  N       
L-Val 9   172.10, qC -   
 10 56.20, CH 4.36, m  11, NH 12, 13 
 11 30.40, CH 2.11, m 10, 12, 13 12, 13 
 12     20.80, CH3 0.82, d (6.6) 11, 13 10, 11, 13 
 13     18.40, CH3 0.84, d (6.6) 11, 12 10, 11, 12 
 NH-14  - 7.77, d (9.5) 10  
N-Me- 14   170.70, qC -   
L-FurAla  15 62.70, CH 4.34, m 20a, 20b 18, 20, 21, 25 
 16 24.68, CH2 a: 2.95, dd (11.3, 15.6)  19, 20b 18, 19, 21, 22, 24 
   b: 3.36, dd (3.3, 15.6) 19, 20a, 24 18, 19, 21, 22, 24 
 17   121.90, qC -   
 18   110.80, CH 6.31, dd (0.9, 1.7) 23, 24 20a, 20b, 24 
 19   144.40, CH 7.44, t (1.7) 22 21, 22, 24 
 20   141.00, CH 7.38,  br s 20b, 22 21, 22, 23  
 21 30.64, CH3 2.78, s  19, 26 
 N       
L-Phe 22   172.50, qC -   
 23 52.20, CH 4.96, m 24a, 24b, NH 24a, 24b 
 24 38.50, CH2 a: 3.20, dd (6.8, 13.9) 23, 24b 22, 23, 25, 26, 30 
   b: 2.72, m 23, 24a 22, 23, 25, 26, 30 
 25  139.00, qC -   
 26  130.40, CH 7.18, m 24a, 27 24a 
  27   128.70, CH 7.24, m 26, 28 25, 26, 28 
 28   126.90, CH 7.17, m 27, 29 26, 27, 29, 30 
 29   128.70, CH 7.24, m 28, 30 25 
 30   130.40, CH 7.18, m 29 24a 
 NH-10 - 7.93, d (9.5) 23  
a 
CD3COCD3, 500/125 MHz. 
b 
Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). 
c
 Numbers refer to proton resonances. 
d
 Numbers refer to carbon resonances. 
e
 Implied 
multiplicities determined by DEPT.  
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Proton and carbon signals for peptide 5 and 5’ were doubled suggesting the presence of 
two isomers. The presence of 3-(3-furyl)-alanine and phenylalanine units was undoubted 
from primal examination of the 1H and 13C NMR spectra (Fig S11 and S12) and was 
verified after detailed analysis of the 2D NMR data. COSY and HMBC correlations revealed 
the presence of two distinct 3-(3-furyl)-alanine residues, one of which showed downfield 
shifted furyl protons, i.e. H-5, H-6 and H-7, and α carbon resonances, i.e C-2, and was 
assigned as N-methyl-3-(3-furyl)-alanine. The other 3-(3-furyl)-alanine was not N-
methylated, as implied from COSY correlations of the α protons, i.e H-10 (δH 4.86) for 
peptide 5 and H-25 (δH 4.76) for peptide 5’, to the corresponding amide protons, i.e. NH-
10 (δH 7.93) for peptide 5 and NH-25 (δH 7.97) for peptide 5’. Residual resonances in the 
aromatic region were assigned to N-methyl-phenylalanine. The last residue was assigned 
as valine and COSY correlations between α proton and amide proton indicated that it was 
not N-methylated.  
This shows that peptide 4 and peptide 5 and 5’ have similar amino acid composition but 
differ in the positioning of the N-methyl substituent. Lastly, sequential relationship of the 
four amino acid residues was deduced from HMBC correlations of the α-protons of the 
amino acid residues and the carbonyl carbon of the adjacent amino acid with HMBC 
correlations of the N-methyl substituents confirming the sequence. Thus, peptide 5 was 
assigned as cyclo-[N-methyl-3-(3-furyl)-alanyl, furylalanyl, N-methyl-phenylalanyl, valinyl] 
and peptide 5’ as cyclo-[N-methyl-3-(3-furyl)-alanyl, valinyl, N-methyl-phenylalanyl, 3-(3-
furyl)-alanyl] (Table 4-5). 
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Table 4-5. 1D NMR spectroscopic data for peptide 5 and 5’. 
Peptide 5: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-3-(3-furyl)-alanyl, (N-methyl-(L)-phenylalanyl), (L)-valinyl] 
Peptide 5’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-phenylalanyl), (L)-3-(3-furyl)-alanyl] 
  Peptide 5   Peptide 5’ 
Amino acid Position   δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
N-Me-L-FurAla 1   170.87, qC -  N-Me-L-FurAla 1 170.25, qC - 
 2     62.77, CH 4.37, m  2   62.57, CH 4.32, m 
 3     24.73, CH2 a: 2.96, dd (8.0, 11.7)  3   24.44, CH2 a: 2.85, dd (8.0, 11.7) 
   b: 3.40, dd (3.3, 8.0)     b: 3.33, dd (3.3, 8.0) 
 4   121.90, qC -  4  121.90, qC - 
 5   110.90, CH 6.36, br s  5  110.90, CH 6.37, br s 
 6   144.40, CH 7.47, t (1.5)  6  144.40, CH 7.52, t (1.5) 
 7   141.10, CH 7.43, br s  7  141.10, CH 7.43, br s 
 8     30.87, CH3 2.79, s  8    30.55, CH3 2.72, s 
  N      N   
L-FurAla 9   172.5, qC -  L-Val 9 172.11, qC - 
 10     51.39, CH 4.86, dt (9.2, 6.9)  10   56.30, CH 4.37, t (8.4) 
 11     27.97, CH2 a: 2.61, m  11   30.28, CH 2.13, m 
   b: 2.97, m  12   20.78, CH3 0.84, d (6.5) 
 12   121.7, qC -  13   18.43, CH3 0.86, d (6.5) 
 13   112.7, CH 6.19, br s  NH-10 - 7.81, d (9.3) 
 14   143.1, CH 7.38, t (1.5)  N-Me-L-Phe 14 170.87, q C - 
 15   141.0, CH 7.13, br s  15   63.59, CH 4.54, dd (3.3, 11.7) 
 NH-10 - 7.93, d (9.8)  16   34.96, CH2 a:3.01, dd (11.7, 15.3) 
N-Me-L-Phe 16 170.25, qC   -    b: 3.65, dd (3.3, 15.3) 
  17   63.46, CH 4.46, dd (3.3, 11.7)  17 138.9, qC - 
 18   34.63, CH2 a: 2.89, dd (11.7, 15.3)   18 129.10, CH 7.26, m 
   b: 3.58, dd (3.3, 15.3)  19 129.40, CH 7.26, m 
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  Peptide 5   Peptide 5’ 
Amino acid Position   δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
 19  138.90, qC -  20 127.50, CH 7.26, m 
 20  129.20, CH 7.26, m  21 129.40, CH 7.26, m 
 21  129.50, CH 7.26, m  22 129.10, CH 7.26, m 
 22  127.50, CH 7.26, m  23   30.87, CH3 2.80, s 
 23  129.50, CH 7.26, m  N   
 24  129.20, CH 7.26, m  L-FurAla 24 172.11, qC - 
 25    30.55 , CH3 2.71, s  25   51.23, CH 4.76, dt (9.2, 6.9) 
 N      26   27.97, CH2 a: 2.50, m 
L-Val 26 171.72, qC -    b: 2.87, m 
 27 56.30, CH 4.23, t (8.4)  27 121.90, qC - 
 28 30.08, CH 2.00, m  28 112.90, CH 6.30, br s 
 29 20.67, CH3 0.69, d (6.5)  29 143.10, CH 7.41, t (1.5) 
 30 18.43, CH3 0.80, d (6.6)  30 141.10, CH 7.27, br s 
  NH-27 - 7.81, d (9.3)  NH-25 - 7.97, d (9.8) 
a
CD3COCD3, 300/75.5 MHz. 
b
 Assignments are based on extensive 1D and 2D NMR experiments (HMBC, HSQC, COSY). 
c
 Implied multiplicities determined by DEPT.  
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Peptides 6 and 6’ and 7 and 7’ showed quite similar 1H and 13C NMR spectra, differing 
only in the resonances observed in the aromatic region. On the basis of HRESIMS data the 
molecular formulae C28H44N4O4 and C26H42N4O5 were assigned for peptides 6 and 6’ and 
peptide 7 and 7’, respectively. Detailed analysis of the NMR data established the presence 
of the branched amino acids valine and two leucines in each peptide. NMR spectra of 
peptide 6 and 6’ (Fig S13 and S14) featured characteristic signals for a phenylalanine 
residue, while those of peptide 7 and 7’ featured signals characteristic for a furyl moiety 
(Fig S15 and S16). Thus the structural difference between both peptides was found to lie 
in the substitution of a phenylalanine moiety in peptide 6 and 6’ with a 3-(3-furyl)-alanine 
in peptide 7 and 7’. This is consistent with a higher hydrophobicity observed in NP-HPLC 
for peptide 6 and 6’ as compared to peptide 7 and 7’. Based on HMBC correlations, the N-
methyl substituents were positioned on the amino acid residues, leucine and the 
aromatic amino acids, i.e. phenylalanine in peptide 6 and 6’ and 3-(3-furyl)-alanine in 
peptide 7 and 7’.  
Detailed interpretation of 2D-NMR spectra revealed that both peptide 6 and 6’ and 
peptide 7 and 7’, consist of inseparable positional isomers, accounting for the proton and 
carbon signals observed in pairs. Thus, peptide 6 was assigned as cyclo-[N-methyl-
phenylalanyl, leucyl, N-methyl-leucyl, valinyl] and peptide 6’ as cyclo-[N-methyl-
phenylalanyl, valinyl, N-methyl-leucyl, leucyl] (Table 4-6). Similarliy, peptide 7 was 
assigned as cyclo-[N-methyl-3-(3-furyl)-alanyl, leucyl, N-methyl-leucyl, valinyl] and 
peptide 7’ as cyclo-[N-methyl-3-(3-furyl)-alanyl, valinyl, N-methyl-leucyl, leucyl] (Table 4-
7). 
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Table 4-6. 1D NMR spectroscopic data for peptide 6 and 6’. 
Peptide 6: (-)-Cyclo-[N-methyl-L-phenylalanyl, (L)-leucyl, (N-methyl-(L)-leucyl), (L)-valinyl] 
Peptide 6’: (-)-Cyclo-[N-methyl-L-phenylalanyl), (L)-valinyl, (N-methyl-(L)-leucyl), (L)-leucyl] 
  Peptide 6   Peptide 6’ 
Amino acid Position   δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
N-Me-L-Phe 1 170.40, qC -  N-Me-L-Phe 1 170.50, qC - 
 2   63.40, CH 4.51, dd (3.7, 11.5)  2 63.70, CH 4.60, dd (3.5, 11.5) 
 3   34.70, CH2 a: 2.96, dd (11.5, 15.0)  3 34.80, CH2 a: 2.98, dd (11.5, 15.0) 
   b: 3.62, dd (3.5, 15.0)    b: 3.67, dd (3.5, 15.0) 
 4 139.10, qC -  4 139.50, qC - 
 5 129.10, CH 7.25, m  5 129.10, CH 7.25, m 
 6 129.40, CH 7.30, t (7.5)  6 129.40, CH 7.30, t (7.5) 
 7 127.40, CH 7.20, t (7.3)  7 127.50, CH 7.20, t (7.3) 
 8 129.40, CH 7.30, t (7.5)  8 129.40, CH 7.30, t (7.5) 
 9 129.10, CH 7.25, m  9 129.10, CH 7.25, m 
 10   30.50, CH3 2.73, s  10   30.50, CH3 2.79, s 
  N      N   
L-Leu 11  172.00, qC -  L-Val 11 172.60, qC - 
 12    48.80, CH 4.60, m  12   55.93, CH 4.26, m 
 13    42.00, CH2 a: 1.19, m  13   30.50, CH 2.00, m 
   b: 1.54, m  14   20.80, CH3 0.68, d (6.7) 
 14    25.00, CH 1.66, m  15   18.40, CH3 0.76, d (6.7) 
 15    23.20, CH3 0.92, d (6.7)  NH-12  7.70, d (8.8) 
 16    22.47, CH3 0.97, d (6.7)  N-Me-L-Leu 16 172.00, qC - 
 NH-12 - 7.79, d (8.8)  17   60.00, CH 4.26, dd (3.7, 11.4) 
N-Me-L-Leu 17 171.49, qC -  18   38.10, CH2 a: 1.77, m 
 18   60.00, CH 4.18, dd (3.7, 11.4)     b:1.95, m 
 19   37.95, CH2 a: 1.74, m  19   25.64, CH 1.43, m 
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  Peptide 6   Peptide 6’ 
Amino acid Position   δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
   b: 1.93, m  20    23.60, CH3 0.95, d ( 6.7) 
 20   25.55, CH 1.41, m  21   22.50, CH3 0.97, d (6.7) 
 21   23.20, CH3 0.76, d (6.7)  22   30.80, CH3 2.74, s 
 22   22.50, CH3 0.80, d (6.7)  N   
 23   30.40, CH3 2.71, s  L-Leu 23 173.10, qC - 
 N    24   49.40, CH 4.90, m 
L-Val 24 172.40, qC -  25   42.25, CH2 a: 1.41, m 
 25   56.40, CH 4.58, m    b: 1.79, m 
 26   31.40, CH 2.25, m  26   25.07, CH 1.66, m 
 27   20.90, CH3 0.92, d (6.7)  27   23.27, CH3 0.92, d (6.7) 
 28   18.50, CH3 0.96, d (6.7)  28   22.47, CH3 0.97, d (6.7) 
 NH-25 - 7.81, d (8.8)  NH-24 - 7.88, d (8.8) 
a 
CD3COCD3, 300/75.5 MHz. 
b 
Assignments are based on extensive 1D and 2D NMR experiments (HMBC, HSQC, COSY). 
c
 Implied multiplicities determined by DEPT.  
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Table 4-7. 1D NMR spectroscopic data for peptide 7 and 7’.  
Peptide 7: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-leucyl, (N-methyl-(L)-leucyl), (L)-valinyl] 
Peptide 7’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-leucyl), (L)-leucyl] 
  Peptide 7   Peptide 7’ 
Amino acid Position   δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
N-Me-L-FurAla 1 170.60, qC -  N-Me-L-FurAla 1 170.33, qC - 
 2    62.70, CH 4.40, dd (3.3, 11.7)   2   62.50, CH 4.37, dd (3.3, 11.7) 
 3    24.20, CH2 a: 2.94, m  3   24.40, CH2 a: 2.92, m 
   b: 3.38, m    b: 3.36, m 
 4 122.10, qC -  4 122.20, qC - 
 5 110.90, CH 6.35, br s  5 111.00, CH 6.36, br s 
 6 144.40, CH 7.50, t (1.65)  6 144.50, CH 7.50, t (1.65) 
 7 141.00, CH 7.41, br s  7 141.10, CH 7.42, br s 
 8   30.50, CH3 2.78, s  8   30.60, CH3 2.78, s 
  N      N   
L-Leu 9   173.09, qC -  L-Val 9 172.29, qC - 
 10     49.40, CH 4.88, m  10   55.90, CH 4.37, t (9.0) 
 11     42.00, CH2 a: 1.39, m  11   30.50, CH 2.11, m 
   b: 1.77, m  12   20.76, CH3 0.81, d (6.7) 
 12     25.08, CH 1.64, m  13   18.40, CH3 0.82, d (6.7) 
 13     23.50, CH3 0.92, d (6.7)  NH-10  7.70, d (9.5) 
 14     22.50, CH3 0.95, d (6.7)  N-Me-L-Leu 14 171.80, qC - 
 NH-10 - 7.90, d (9.5)  15   60.00, CH 4.26, dd (3.7, 11.4) 
N-Me-L-Leu 15 171.40, qC -  16   38.00, CH2 a: 1.77, m 
 16   60.00, CH 4.18, dd (3.7, 11.4)     b:1.95, m 
 17   38.10, CH2 a: 1.74, m  17   25.70, CH 1.40, m 
   b: 1.93, m  18    23.50, CH3 0.96, d ( 6.7) 
 18   25.60, CH 1.40, m  19   21.40, CH3 0.97, d (6.7) 
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  Peptide 7   Peptide 7’ 
Amino acid Position   δC, mult.
a, b, c
 δH
a, b
 (J in Hz) Amino acid Position δC, mult.
a, b, c
 δH
a, b
 (J in Hz) 
 19   23.30, CH3 0.81, d (6.7)  20   30.80, CH3 2.74, s 
 20   22.50, CH3 0.84, d (6.7)  N   
 21   30.40, CH3 2.71, s  L-Leu 21 173.00, qC - 
 N    22   49.00, CH 4.70, m 
L-Val 22 172.30, qC -  23   42.20, CH2 a: 1.27, m 
 23   56.40, CH 4.56, t (9.0)    b: 1.63, m 
 24   30.50, CH 2.25, m  24   25.11, CH 1.64, m 
 25   20.90, CH3 0.90, d (6.7)  25   23.30, CH3 0.92, d (6.7) 
 26   18.45, CH3 0.94, d (6.7)  26   22.50, CH3 0.95, d (6.7) 
 NH-23 - 7.81, d (9.5)  NH-22 - 7.80, d (9.5) 
a 
CD3COCD3, 500/125 MHz. 
b
 Assignments  are based on extensive 1D and 2D NMR experiments (HMBC, HSQC, COSY). 
c
 Implied multiplicities determined by DEPT.  
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1H and 13C NMR spectra of peptide 8 (Fig S17 and S18) and peptide 9 (Fig S19 and S20) 
displayed various resemblances, including two amide carbonyl carbon resonances 
(between δC 165 - 168), two α proton signals (between δH 3.6 - 4.3) and a down-field 
shifted methyl singlet (around δH 3.0 / δC 33.0), together with proton and carbon 
resonances in the aromatic region, all concluding the presumption of an N-methylated 
dipeptide molecule incorporating an aromatic moiety. Additionally, both compounds 
showed an ion peak at m/z of 297.1568 [M+Na]+ and 297.1555 [M+Na]+, for peptide 8 and 
peptide 9, respectively, using HRESIMS, suggesting they share the same elemental 
composition. They have a molecular formula of C16H22N2O2, indicating seven degrees of 
unsaturation. 13C NMR and DEPT135 spectra revealed 16 resonances, resulting from three 
methyls, two methylenes, three sp3 methines, five sp2 methines and three quaternary 
carbons. Comprehensive analysis of the 1D and 2D NMR spectroscopic data uncovered 
the identity of the two amino acid residues, as leucine and phenylalanine. Placement of 
the methyl functionality was based on COSY and HMBC correlations of the N-methyl 
substituent with their adjacent carbonyl carbons and α-protons, i.e. for peptide 8, NCH3-
16 to qC-1 and αCH-8, and for peptide 9, NCH3-7 to qC-8 and αCH-2. This accounts for the 
shifted resonances observed for the α-carbons of the leucine and phenylalanine residues. 
For peptide 8, the αCH-8 carbon resonance (δC 64.3) of the phenylalanine residue was 
shifted downfield indicating that this unit was N-methylated. In turn the αCH-2 carbon 
resonance (δC 60.5) of the leucine residue of peptide 9 was shifted downfield indicating 
that leucine was N-methylated. Their cyclic structure was deduced from HMBC 
correlations of αCH-2 (δH/δC 3.64/54.1) to qC-7 (δC 166.8), αCH-8 (δH/δC 4.21/64.3) to qC-1 
(δC 167.2) and NCH3-16 (δH/δC 3.03/32.9) to qC-1 for peptide 8 and of αCH-2 (δH/δC 
3.61/60.5) to qC-8 (δC 165.8), αCH-9 (δH/δC 4.26/57.6) to qC-1 (δC 167.60) and NCH3-7 
(δH/δC 2.85/32.6) to qC-8 for peptide 9. Thus, peptide 8 was assigned as cyclo-(leucyl, N-
methyl-phenylalanyl) (Table 4-8) and peptide 9 as cyclo-(N-methyl-leucyl, phenylalanyl) 
(Table 4-9), diketopiperazines varying in the positioning of the N-methyl substituent.     
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Table 4-8. 1D and 2D NMR spectroscopic data for peptide 8, (-)-Cyclo-[(L)-leucyl, N-methyl-(L)-phenylalanyl]. 
Amino acid Position    δC, mult.
a, b, e
 δH
a, b
 (J in Hz) COSY
a, c
 HMBC
a, d
 
L-Leu 1   167.20, qC -   
 2 54.10, CH 3.64, ddd (3.7, 4.8, 9.8) 3a,3b, NH-2 1, 3, 4 
 3 45.60, CH2 a: -0.11, ddd (4.8, 9.9, 13.9)  2, 3b, 4 1, 2, 4, 5, 6 
   b: 0.75, ddd (4.4, 9.5, 13.9) 2, 3a, 4 1, 2, 4, 5, 6 
 4 24.50, CH 1.48, m 3a, 3b, 5, 6 3 
 5 21.80, CH3 0.70, d (6.6) 3a, 4, 6 3, 4, 6 
 6 23.70, CH3 0.65, d (6.6) 4, 5 3, 4, 5 
 NH      
N-Me- 7   166.80, qC -   
L-Phe 8 64.30, CH 4.21, t (4.4) 9a, 9b, 16 7, 9, 10, 16 
 9 37.60, CH2 a: 3.24, dd (4.4, 13.9) 8, 9b 7, 8, 10, 11, 15,16 
   b: 3.18, dd (4.4, 13.9) 8, 9a,11, 15  7, 8, 10, 11, 15, 16 
 10   137.50, qC -   
 11   131.40, CH 7.13, dd (2.2, 7.7) 12 9, 10, 12, 13, 15 
 12   129.60, CH 7.29, t (7.7)  11, 13 10, 11, 13, 14 
 13   128.30, CH 7.25, t (7.7) 12, 14 11, 12, 14, 15 
 14   129.60, CH 7.29, t (7.7) 13, 15 10, 12, 13, 15 
 15   131.40, CH 7.13, dd (2.2, 7.7) 14 9 
 16     32.90, CH3 3.03, s 8 1, 8, 9 
 N     
a 
CD3COCD3, 300/75.5 MHz. 
b 
Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). 
c
 Numbers refer to proton resonances. 
d
 Numbers refer to carbon resonances. 
e
 Implied 
multiplicities determined by DEPT.  
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Table 4-9. 1D and 2D NMR spectroscopic data for peptide 9, (-)-Cyclo-[N-methyl-(L)-leucyl, (L)-phenylalanyl]. 
Amino acid Position    δC, mult.
a, b, e
 δH
a, b
 (J in Hz) COSY
a, c
 HMBC
a, d
 
N-Me-L-Leu 1   167.60, qC -   
 2     60.50, CH 3.61, dd (3.7, 9.2) 3b 3a, 3b, 7 
 3     42.70, CH2 a: 0.96, ddd (4.0, 9.3, 13.8) 3b, 4 2, 5, 6 
   b: 0.47, ddd (4.6, 9.5, 13.8) 2, 3a 2, 5, 6 
 4 25.50, CH 1.70, m 3a, 5, 6 2, 3a, 3b 
 5 23.30, CH3 0.69, d (6.5) 4, 6 3a, 3b, 6 
 6 21.80, CH3 0.81, d (6.5) 4, 5 3a, 3b, 5 
 7 32.60, CH3 2.85, s  2 
 N     
 L-Phe 8   165.80, qC -   
 9     57.60, CH 4.26, m 10a, 10b 10a, 10b 
 10     40.40, CH2 a: 3.18, dd (5.5, 13.4) 9, 10b 9, 11, 12, 16 
   b: 3.00, dd (4.7, 13.4) 9, 10a 9, 11, 12, 16 
 11   137.50, qC -  10a, 10b, 12, 16 
 12   131.10, CH 7.18, d  (7.7)  13, 14 11, 13 
 13   129.20, CH 7.29, t  (7.7) 12, 14 14 
 14   127.80, CH 7.23, m 13, 15 13, 15 
 15   129.20, CH 7.29, t (7.7) 14, 16 14, 16 
 16   131.10, CH 7.18, d (7.7) 14, 15 11, 15 
 NH     
a 
CD3COCD3, 500/125 MHz. 
b 
Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). 
c
 Numbers refer to proton resonances. 
d
 Numbers refer to carbon resonances. 
e
 Implied 
multiplicities determined by DEPT.  
 
The absolute configuration of the amino acids in the isolated peptides, i.e. peptide 1 and 
1’, peptide 2, peptide 3 and peptide 4, were assigned after acidic hydrolysis followed by 
derivatization of the amino acids with Marfey’s reagent and HPLC analysis (see 3.4.6). 
Based on comparison of retention times to standard amino acids we could assign the L-
configuration to the amino acids valine, leucine and phenylalanine (Fig S42-S45). As for 
the 3-(3-furyl)-alanine moiety for which no standard was available, an L-configuration was 
suggested as determined earlier from X-ray crystallography of endolide A (Fig 4-2), a cyclic 
tetrapeptide formerly isolated from the same fungal strain.96 For those peptides isolated 
in lower quantities, i.e. peptide 5 and 5’, peptide 6 and 6’, peptide 7 and 7’, peptide 8 and 
peptide 9, it was not possible to establish the absolute configuration of the amino acid 
residues, however based on biogenetic origin an L-configuration is implied for them.   
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Fig 4-2. Endolide A, cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), L-valinyl, (N-methyl-(L)-3-(3-furyl)-alanyl), L-
leucyl], cyclic tetrapeptide formely isolated from the Stachylidium sp.
96
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Fig 4-3. Structures of the isolated cyclic peptides. 
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Peptides isolated 
Peptide 1 and 1’, cyclic tetrapeptide, peptide 1 (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), 
(L)-leucyl, (N-methyl-(L)-phenylalanyl), (L)-valinyl] and peptide 1’ (-)-Cyclo-[(N-methyl-(L)-
3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-phenylalanyl), (L)-leucyl]: white solid (2.5 mg 
L-1), [α] D
23 -133 (c 0.44, MeOH); UV (MeOH) λmax 204 nm (log Є 4.69); IR (ATR) νmax 3345 
(br), 2958, 2871, 1704, 1660, 1511, 1364, 1089 cm-1; 1H NMR and 13C NMR (Table 4-1); 
LRESIMS m/z 525.5 [M+H]+, m/z 523.9 [M-H]-; HRESIMS m/z 547.2902 [M+Na]+ (calcd. for 
C29H40N4NaO5, 547.2896). 
Peptide 2, cyclic tetrapeptide, (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-furylalanyl, N-
methyl-(L)-phenylalanyl, (L)-valinyl]: white solid (1.5 mg L-1), [α] D
23 -129 (c 0.2, MeOH); UV 
(MeOH) λmax 204 nm (log Є 3.45); IR (ATR) νmax 3330 (br), 2961, 2360, 1704, 1660, 1514, 
1362, 1091 cm-1; 1H NMR and 13C NMR (Table 4-2); LRESIMS m/z 559.4 [M+H]+, m/z 557.6 
[M-H]-; HRESIMS m/z 581.2731 [M+Na]+ (calcd. for C32H38N4NaO5, 581.2740). 
Peptide 3, cyclic tetrapeptide, (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-phenylalanyl, N-
methyl-(L)-phenylalanyl, (L)-valinyl]: white solid (1 mg L-1), [α] D
23 -153 (c 0.125, MeOH); 
UV (MeOH) λmax 207 nm (log Є 3.06); IR (ATR) νmax 3329 (br), 2961, 1703, 1659, 1512, 
1362, 1090 cm-1; 1H NMR and 13C NMR (Table 4-3); LRESIMS m/z 569.7 [M+H]+, m/z 567.7 
[M-H]-; HRESIMS m/z 569.3119 [M+H]+ (calcd. for C34H41N4O4, 569.3128). Data are in 
accordance with those in literature.95 
Peptide 4, cyclic tetrapeptide, (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-
methyl-(L)-3-(3-furyl)-alanyl), (L)-phenylalanyl]: white solid (1.4 mg L-1), [α] D
23 -76 (c 
0.058, MeOH); UV (MeOH) λmax 204 nm (log Є 3.62); IR (ATR) νmax 3331 (br), 2926, 2359, 
1660, 1505, 1386, 1090 cm-1; 1H NMR and 13C NMR (Table 4-4); LRESIMS m/z 549.4 
[M+H]+, m/z 547.5 [M-H]-; HRESIMS m/z 571.2532 [M+Na]+ (calcd. for C30H36N4NaO6, 
571.2533). 
Peptide 5 and 5’, cyclic tetrapeptide, peptide 5 (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), 
(L)-3-(3-furyl)-alanyl, (N-methyl-(L)-phenylalanyl), (L)-valinyl] and peptide 5’ (-)-Cyclo-[(N-
methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-phenylalanyl), (L)-3-(3-furyl)-
alanyl]: white solid (0.6 mg L-1), [α] D
23 -110 (c 0.166, MeOH); UV (MeOH) λmax 204 nm (log 
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Є 3.41); IR (ATR) νmax 3331 (br), 2925, 2358, 1663, 1515, 1401, 1088 cm
-1; 1H NMR and 13C 
NMR (Table 4-5); LRESIMS m/z 549.4 [M+H]+, m/z 547.5 [M-H]-; HRESIMS m/z 571.2526 
[M+Na]+ (calcd. for C30H36N4NaO6, 571.2533). 
Peptide 6 and 6’, cyclic tetrapeptide, peptide 6 (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-
leucyl, N-methyl-(L)-leucyl, (L)-valinyl] and peptide 6’ (-)-Cyclo-[N-methyl-(L)-phenylalanyl, 
(L)-valinyl, N-methyl-(L)-leucyl, (L)-leucyl]: white solid (0.6 mg L-1), [α] D
23 -105 (c 0.108, 
MeOH); UV (MeOH) λmax 206 nm (log Є 3.03); IR (ATR) νmax 3332 (br), 2957, 2358, 1667, 
1507, 1456 cm-1; 1H NMR and 13C NMR (Table 4-6); LRESIMS m/z 501.4 [M+H]+, m/z 499.4 
[M-H]-; HRESIMS m/z 501.3438 [M+H]+ (calcd. for C28H45N4O4, 501.3441). 
Peptide 7 and 7’, cyclic tetrapeptide, peptide 7 (-)-Cyclo-[N-methyl-(L)-3-(3-furyl)-alanyl, 
(L)-leucyl, N-methyl-(L)-leucyl, (L)-valinyl] and peptide 7’ (-)-Cyclo-[N-methyl-(L)-3-(3-
furyl)-alanyl, (L)-valinyl, N-methyl-(L)-leucyl, (L)-leucyl]: white solid (0.6 mg L-1), [α] D
23 -67 
(c 0.083, MeOH); UV (MeOH) λmax 204 nm (log Є 3.12); IR (ATR) νmax 3342 (br), 2924, 2359, 
1714, 1652, 1520, 1365 cm-1; 1H NMR and 13C NMR (Table 4-7); LRESIMS m/z 491.9 
[M+H]+, m/z 489.8 [M-H]-; HRESIMS m/z 513.3045 [M+Na]+ (calcd. for C26H42N4NaO5, 
513.3053). 
Peptide 8, diketopiperazine, (-)-Cyclo-[(L)-leucyl, N-methyl-(L)-phenylalanyl]: white solid 
(0.35 mg L-1), [α] D
23 -14 (c 0.083, MeOH); UV (MeOH) λmax 203 nm (log Є 3.12); IR (ATR) 
νmax 3198 (br), 2954, 2924, 2359, 1678, 1455, 1326 cm
-1; 1H NMR and 13C NMR (Table 4-8); 
LRESIMS m/z 275.6 [M+H]+, m/z 273.4 [M-H]-; HRESIMS m/z 297.1568 [M+Na]+ (calcd. for 
C16H22N2NaO2, 297.1579). 
Peptide 9, diketopiperazine, (-)-Cyclo-[N-methyl-(L)-leucyl, (L)-phenylalanyl]: white solid 
(0.15 mg L-1), [α] D
23 -241 (c 0.066, MeOH); UV (MeOH) λmax 203 nm (log Є 2.85); IR (ATR) 
νmax 3248 (br), 2925, 2359, 1681, 1455, 1340 cm
-1; 1H NMR and 13C NMR (Table 4-9); 
LRESIMS m/z 275.6 [M+H]+, m/z 273.4 [M-H]-; HRESIMS m/z 297.1555 [M+Na]+ (calcd. for 
C15H20N2NaO2, 297.1573). 
 
 
Results 
62 
 
4.3 Biosynthetic studies of secondary metabolites from Stachylidium sp. 
Cyclic peptides  
For studying the biosynthesis of the cyclic peptides, peptide 1 and 1’ (Fig 4-4) was chosen 
as a prototype, on the grounds that it incorporates all the four amino acid building blocks. 
A closer look into the structural architecture of the isolated peptides proposed a non-
ribosomal biosynthetic origin, implied from the incorporated modified amino acid 
residues, i.e. N-methylated, and the unusual non-proteinogenic amino acid, i.e. 3-(3-
furyl)-alanine. Three of the four amino acids, i.e. valine, leucine and phenylalanine, are 
discernibly derived from proteinogenic amino acids modified by methylation as seen in 
phenylalanine. Of special interest was the remaining amino acid, 3-(3-furyl)-alanine, a 
rare building block reported before in heptapeptides from the fungus Rhizopus 
microsporus68 and more recently in the pentapeptide bingchamide B from Streptomyces 
bingchenggensis.74 We thus set up to determine the biosynthetic origin of the 3-(3-furyl)-
alanine, and propose a biosynthetic scheme for its biosynthesis, not investigated before, 
employing classical isotope tracer experiments.  
 
Fig 4-4. Structures of the positional isomers peptide 1 and 1’. 
Polyketides 
The marilones and marilines are polyketide compounds with a phthalide and 
phthalimidine skeleton, respectively (Fig 4-5).83,84 This type of compound class is known to 
be produced by polyketide synthase (PKS) biosynthetic machineries, using acetate as 
basic building blocks in a Claisen-type condensation reaction to expand the growing 
ketide chain.97 Precedent biosynthetic studies for the phthalide skeleton, such as in 
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mycophenolic acid,98 nidulol and silvaticol,99 proved the tetraketide nature of the 
phthalide skeleton, while no biosynthetic studies were conducted for phthalimidine 
metabolites, which probably follows a similar biosynthetic route. An unusual structural 
feature in both the marilones and marilines is the methyl substituent at C-8. This could be 
postulated to be introduced either from a propionate starter unit, by methylation of an 
acetate starter unit, or by loss of a carbon unit from a pentaketide intermediate, generally 
not known in fungal polyketide biosynthesis. Thus, biosynthetic studies would help to 
resolve this ambiguity.  
 
Fig 4-5. Structures of isolated polyketides, marilone A and mariline B. 
4.3.1 Preliminary feeding experiments  
Biosynthetic feeding studies in marine organisms are generally known to be faced with 
major difficulties.100,101 These are related to the producing microorganisms, which are 
usually slow growing under laboratory conditions with low amounts of metabolites being 
produced. Another facet is related to the used feeding protocol, which includes the 
choice of growth media, and the concentration and the time of feeding the precursors. 
Liquid media have generally been regarded as the media of choice in biosynthetic studies, 
as they ensure adequate distribution of the fed precursors. The amount of fed precursor 
should be sufficient for being incorporated and analytically detected in the final 
metabolite, and at the same time not too high as to hamper biosynthesis or to be toxic 
for the growing microorganism. Lastly, the time course of feeding the precursor should be 
adjusted, as biosynthesis of secondary metabolites usually follows primary metabolism 
after the microorganism has fully developed.10 Therefore, a too early feeding of a single 
precursor dose may be used up in primary metabolism, and thus multiple feeding after 
sufficient microorganism growth could likely overcome this hurdle.  
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To address these difficulties, preliminary experiments were initiated in both solid and 
liquid biomalt salt culture media, with and without the putative precursors of interest 
(see 3.5.1 for experimental details). The aim was to determine the onset of metabolite 
production and to investigate possible changes in the level of metabolite production 
before proceeding further with biosynthetic experiments. Information gained from these 
preliminary experiments was essential in setting up a successful feeding protocol that 
would ensure maximal incorporation of the labeled precursors into the metabolites of 
interest.  
From the time-scale experiment, we tracked the production of secondary metabolites, 
where solid biomalt salt cultures were harvested at different time points and analyzed 
using LC-MS. The peptides were starting to be detected at around day 9, with the 
amounts increasing with fungal growth, becoming highly distinct at around day 30, and 
still being clearly detected throughout the 55 days cultivation period. As for the 
polyketides, i.e. marilones and marilines, they were starting to be produced at a fairly 
later stage, around day 20, in clearly lower amounts compared to the peptides (Table 4-
10).  
Table 4-10. Production of secondary metabolites on solid biomalt salt medium as implied from LC-MS 
results of time-scale experiment. 
Day Peptides
1 
Polyketides
2 
5 - - 
9 + - 
14 ++ - 
20 ++ + 
30 +++ + 
55 +++ ++ 
1
 for structures see Fig 4-3, 
2
 for structures see Fig 4-5 
 
 
Liquid culture medium was found unsuitable for further biosynthetic studies as 
preliminary experiments in liquid biomalt salt culture medium showed the absence of 
some of the major metabolites of interest, i.e. peptides with a 3-(3-furyl)-alanine amino 
acid.  
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Addition of general precursors normally employed in biosynthetic studies such as glucose, 
glycerol, shikimic acid or sodium acetate, did not exhibit any deleterious effect on the 
growing fungus, or noticeably affect the amount of metabolite produced. On the other 
hand, addition of phenylalanine clearly led to an increased production of those peptides 
incorporating a phenylalanine residue.  
From a liquid biomalt salt culture medium supplemented with phenylalanine two 
compounds, hitherto not encountered in this fungus, were isolated (see 3.5.2). Through 
the interpretation of the NMR data (Fig S21-S24 and Table S1) and literature search, they 
were assigned as bisdethiobis(methylthio)-acetylaranotin (BDA) and 
bisdethiobis(methylthio)-acetylapoaranotin (BDAA), thiodiketopiperazines previously 
reported from the fungi Arachniotus aureus and Aspergillus terreus (Fig 4-6).102 Their 
biosynthesis involves a phenylalanine intermediate, thus supplementing the culture 
media with phenylalanine, probably stimulated their production.103 They belong to the 
group of epipolythiodioxopiperazines, a class of fungal toxins, featuring a seven 
membered 4,5-dihydrooxepine ring, with absence of a disulfide bridge. They were tested 
for antimicrobial activity against Escherichia coli, Bacillus megaterium, Microbotryum 
violaceum, Eurotium rubrum and Mycotypha microspora and were found to be inactive 
(see 3.6.1 for experimental details).  
 
Fig 4-6. Isolated epipolythiodioxopiperazines from liquid biomalt medium fed with phenylalanine.   
Based on observations from the preliminary experiments, a biosynthetic feeding protocol 
on solid biomalt salt culture media was established (Table 4-11). For the peptides a twice 
feeding starting on day 5, supplemented with a second feeding on day 10 and harvesting 
after a 30 day period would be optimal, to avoid dilution of the labeled peptides with 
unlabeled peptides. For the polyketides, a longer cultivation period of around 60 days 
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would be necessary and a thrice feeding starting on day 10, as to avoid consumption of 
the labeled precursor in primary metabolism, and on days 20 and 30 would ensure a 
stable supply of the labeled precursors during polyketide biosynthesis.   
Table 4-11. Established feeding protocol for labeled precursors based on observations from preliminary 
experiments. 
Day Peptides
1
 Polyketides
2
 
1 Fungal Inoculation 
5 1
st
 feeding  
10 2
nd 
feeding 1
st
 feeding 
20  2
nd
 feeding 
30 Harvesting & Extraction 3
rd
 feeding 
60  Harvesting & Extraction 
1
 for structures see Fig 4-3, 
2
 for structures see Fig 4-5 
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4.3.2 Biosynthetic/Metabolic origin of building blocks in peptide 1 and 1’ 
For the experimental investigation of any biosynthetic pathway, it is necessary to 
establish a hypothetical biosynthetic scheme for the conversion of fed precursors into the 
target metabolite. Our first hypothesis was based on the structural relationship between 
the 3-(3-furyl)-alanine and the phenylalanine skeleton and points to the possibility of 3-(3-
furyl)-alanine being derived by ring cleavage of a phenylalanine intermediate, notably 
that both amino acid moieties are incorporated into the isolated peptides. As little was 
known about the biosynthetic origin of 3-(3-furyl)-alanine, a general carbon source 
precursor involved in several biosynthetic pathways, such as glucose or glycerol, could 
help in delineating the involved biosynthetic pathway. This approach was supported by 
earlier biosynthetic studies on the reductiomycin antibiotic produced by Streptomyces 
xanthochromogenus, in which they fed labeled glycerol to study the biosynthetic origin of 
the dihydrofuranacrylic acid moiety of reductiomycin,104 which shares the basic skeleton 
with 3-(3-furyl)-alanine. Their results point to the shikimate pathway as the origin for the 
dihydrofuranacrylic acid moiety. To test our hypotheses, stable isotope precursors labeled 
at one or more positions were fed to the growing fungal culture (see 3.5 for experimental 
details), followed by extraction and isolation of the metabolites of interest using VLC 
fractionation and HPLC techniques (see 3.3 for chromatographic isolation details and Fig 
4-1 for isolation scheme). The labeling pattern was then established using NMR and mass 
spectroscopic techniques (see 3.4). With mass spectrometry we could detect the mass 
difference between natural abundance isotopic distribution and isotopically enriched 
molecules, although the exact site of incorporation cannot be deduced.105 While with 13C-
NMR spectroscopy, incorporation of a precursor containing 13C at more than natural 
abundance, i.e. more than 1.1%, in a specific position gives rise to an enhanced signal in 
the 13C-NMR spectra as compared to those carbons of natural abundance. The labeling 
pattern can thus be deduced by comparing the 13C-NMR spectrum of the labeled 
metabolite with the spectrum of the unlabeled metabolite.106  
4.3.2.1 Labeling studies with [1-13C]phenylalanine  
By feeding [1-13C]phenylalanine, we tested whether phenylalanine, an aromatic amino 
acid of shikimate biosynthetic origin, could be a plausible intermediate in the biosynthesis 
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of 3-(3-furyl)-alanine (see 3.5.3 for experimental details). Incorporation of fed [1-
13C]phenylalanine in peptide 1 and 1’ was monitored using LC-MS. A signal was observed 
at m/z 526.1 [M+H+1]+, with a 1 Da mass shift compared to the unlabeled control, i.e. m/z 
525.2 [M+H]+ (Fig S36). This was further verified after isolation of peptide 1 and 1’ and 
13C-NMR spectroscopic analysis, where we observed a prominent signal for the carbonyl 
carbon, i.e. C-15 (δc 170.5) and C-14 (δc 170.9), of the phenylalanine residue of peptide 1 
and 1’ (Fig S26). However, no incorporation of the labeled phenylalanine was observed in 
the 3-(3-furyl)-alanine residue (Fig 4-7).  
 
Fig 4-7. Observed 
13
C enrichment in peptide 1 and 1’ after feeding [1-
13
C]phenylalanine. Pink dots indicate 
13
C enriched atoms. 
Validity of this experiment was confirmed with the simultaneous isolation of peptide 3 
(Fig 4-3), which was found to incorporate three [1-13C]phenylalanine units identified as 
three enhanced signals for the carbonyl carbons, i.e. C-1 (δc 171.0), C-11 (δc 172.1), C-20 
(δc 170.1), of the phenylalanine residues in the 
13C-NMR spectrum (Fig S27). Along with 
that, a 3 Da mass shift was observed for peptide 3 in the LC-MS spectrum of the crude 
extract of the Stachylidium sp. culture supplemented with [1-13C]phenylalanine. Labeled 
peptide 3 showed a signal at m/z 572.4 [M+H+3]+ compared to the unlabeled control, i.e. 
m/z 569.2 [M+H]+ (Fig S37). 
4.3.2.2 Labeling studies with [U-13C] glycerol 
Feeding fully labeled [U-13C]glycerol gave a complex 13C-NMR spectrum (Fig S28) for the 
isolated peptide 1 and 1’ (see 3.5.4 for experimental details). Detailed analysis of the 
signal pattern and 13C-13C coupling constants in the inverse gated proton decoupled 13C-
NMR spectrum of the 3-(3-furyl)-alanine moiety of peptide 1 and 1’ showed the presence 
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of two doubly coupled spin systems, i.e. C-1/C-2/C-3 and C-5/C-4/C-7, and a single 
enriched non-coupled signal for C-6 (Fig 4-8). For detailed chemical shifts and coupling 
constants see Table S2 and S3 for [U-13C]glycerol-derived peptide 1 and 1’, respectively.  
 
Fig 4-8. Observed 
13
C-labeling pattern for the 3-(3-furyl)-alanine moiety of peptide 1 and 1’ from the 
experiment with [U-
13
C]glycerol: bold lines indicate 
13
C labeled isotopomers with directly adjacent 
13
C 
atoms, arrows indicate 
13
C atoms connected by long-range coupling and their corresponding coupling 
constants (J values) in Hz. Dots indicate 
13
C enriched atoms. 
From the established metabolic fate of glycerol, glycolysis gives rise to an intact three-
carbon unit in the form of phosphoenolpyruvate.104 Concurrently, glycerol is converted in 
the reductive pentose phosphate (RPP) cycle, via dihydroxyacetone phosphate and 
phosphoglyceraldehyde into fructose-6-phosphate, which contains two coupled three-
carbon units, which with the help of a transketolase gives erythrose-4-phosphate with 
one intact three-carbon units and a single non-coupled carbon (Fig 4-9).107 
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Fig 4-9. Formation of PEP and E-4-P from [U-
13
C]glycerol via the glycolytic and RPP pathway and their 
incorporation into 3-(3-furyl)-alanine and phenylalanine of peptide 1 and 1’. Bold lines indicate 
13
C labeled 
isotopomers with directly adjacent 
13
C atoms. Dots indicate 
13
C enriched atoms. 
4.3.2.3 Labeling studies with [1-13C]glucose  
The observed labeling pattern in the [U-13C]glycerol experiment was further supported by 
feeding studies using [1-13C]glucose (see 3.5.5 for experimental details). We observed 
enriched signals for C-3 (δc 24.5) and C-5 (δc 110.9) of the 3-(3-furyl)-alanine moiety of 
peptide 1 and 1’ (Fig S29). These originate from [3-13C]phosphoenolpyruvate via glycolysis 
and [4-13C]erythrose-4-phosphate via the pentose phosphate pathway, following 
conversion of [1-13C]glucose to [6-13C]glucose-6-phosphate or [1,6-13C]glucose-6-
phosphate via glycolysis and gluconeogenesis (Fig 4-10).108 
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Fig 4-10. Formation of PEP and E-4-P from [1-
13
C]glucose via the glycolytic and pentose phosphate pathway 
and their incorporation into 3-(3-furyl)-alanine and phenylalanine of peptide 1 and 1’. Dots indicate 
13
C 
enriched atoms originating from [1-
13
C]glucose. 
Thus, the observed labeling pattern after feeding [U-13C]glycerol and [1-13C]glucose points 
to a shikimate-related pathway for the biosynthesis of 3-(3-furyl)-alanine, from 
condensation of phosphoenolpyruvate and erythrose-4-phosphate with 3-deoxy-D-
arabino-heptulosonic acid-7-phosphate as an intermediate (Fig 4-11).  
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Fig 4-11. Summary of 
13
C enrichment pattern in the 3-(3-furyl)-alanine moiety of peptide 1 and 1’ from a 
biomalt salt agar culture of Stachylidium sp. labeled with both [1-
13
C]glucose and [U-
13
C]glycerol in separate 
experiments. Bold lines indicate 
13
C-labeled isotopomers with directly adjacent 
13
C atoms. Dots indicate 
13
C 
enriched atoms. 
4.3.2.4 Labeling studies with [1,7-13C]shikimic acid  
For the verification of the shikimate origin of 3-(3-furyl)-alanine, [1,7-13C]shikimic acid was 
chosen to be fed (see 3.5.8 for experimental details). However, no labeled 3-(3-furyl)-
alanine and phenylalanine could be observed in LC-MS (Fig S38(B)). Failure of this 
experiment can be attributed to several reasons. The applied feeding protocol, i.e. a too 
low concentration, or the impermeability of fungal cells to labeled shikimic acid are 
plausible explanations. The latter was previously reported from several biosynthetic 
studies109 and was thought more likely as the added labeled shikimic acid was detected 
intact in the fungal crude extract. Thus results of this experiment were not predictive (Fig 
4-12).  
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Fig 4-12. Predicted labeling patterns for the 3-(3-furyl)alanine and phenylalanine moieties of peptide 1 and 
1’ from the experiment with [1,7-
13
C]shikimic acid. Bold lines indicate 
13
C-labeled isotopomers with directly 
adjacent 
13
C atoms. Dots indicate 
13
C enriched atoms. Unfortunately, the conducted labeling experiment did 
not result in any incorporation  
4.3.2.5 Feeding studies with halogenated precursors and proteinogenic amino acids  
Earlier studies have investigated the use of halogenated precursors as a biosynthetic label 
benefiting from their low cost in comparison to 13C labeled precursors.110 Additionally, the 
incorporation of the halogenated precursors and the isolation of novel metabolite 
analogues with superior and selective biological activity is exploited (precursor directed 
biosynthesis).111 In our continuous search for a plausible intermediate involved in the 
biosynthesis of 3-(3-furyl)-alanine, we fed 2-chloro-protocatechuic acid, with 
protocatechuic acid being a known intermediate in the shikimate pathway. 2-chloro-
protocatechuic acid was synthesized from 2-chloro-3,4-dimethoxybenzoic acid after 
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successful demethylation using BBr3 in dichloromethane (see 3.7.2 for experimental 
details). Added 2-chloro-protocatechuic acid was not seen to be incorporated into 
peptide 1 and 1’, by LC-MS analysis (Fig S38(C)). This indicates failure of incorporation, 
due to its irrelevance to the 3-(3-furyl)-alanine biosynthesis, or because the biosynthetic 
enzymes do not accept chlorinated substrates, or as in the labeled shikimic acid 
experiment due to fungal cell impermeability. Again, results of this experiment were not 
conclusive (see 3.5.2 for experimental details). 
 
Fig 4-13. Proposed incorporation of 2-chloro-protocatechuic acid in the 3-(3-furyl)-alanine moiety. 
Unfortunately, the conducted experiment did not result in any incorporation. 
The involvement of yet another phenolic acid such as 4-hydroxybenzoic acid, a symmetric 
intermediate frequently encountered in the biosynthesis of several metabolites108,112 
including reductiomycin,104 was tested through feeding 2-fluoro-4-hydroxybenzoic acid 
(see 3.5.2 for experimental details), but did not result in any incorporation into peptide 1 
and 1’ as observed in LC-MS (Fig S38(D)). 
However, feeding halogenated ring-substituted phenylalanine such as 2-fluoro-
phenylalanine and 3-fluoro-phenylalanine, resulted in the production of new peptide 
analogues as revealed in LC-MS with a new mass peak at m/z 543.6 [M+19]+, representing 
incorporation of a single fluoro-phenylalanine into peptide 1 and 1’ scaffold. In contrast, 
4-fluoro-phenylalanine and tyrosine (a p-hydroxylated phenylalanine) were not seen to be 
incorporated into the peptides (Fig S39) (see 3.5.2 for experimental details).  
Additionally, the incorporation of alternative amino acids in the peptides was tested by 
feeding several proteinogenic amino acids, such as alanine, glycine, proline, tryptophan, 
tyrosine and serine, to the growing fungus media, but did not result in the detection of 
any further new analogues as seen in LC-MS (see 3.5.2 for experimental details). 
Results 
75 
 
4.3.2.6 Labeling studies with [1-13C]sodium acetate 
Although some carbon atoms of the 3-(3-furyl)-alanine moiety of peptide 1 and 1’ 
displayed some 13C enrichment in the 13C-NMR spectrum after feeding [1-13C]sodium 
acetate, this is not indicative of any known metabolic mechanism (Fig S31). This could be 
attributed to metabolic turnover of [1-13C]sodium acetate during fungal growth. Thus, the 
possibility of a polyketide pathway, which utilizes acetate as a basic building block, being 
involved in the biosynthesis of the 3-(3-furyl)-alanine was deemed implausible (see 3.5.6 
for experimental details).  
4.3.2.7 Labeling studies with [Me-13C]methionine 
[Me-13C]methionine, a universal methylating agent used frequently in biosynthetic 
studies, was supplemented to Stachylidium sp. biomalt salt agar cultures and gave high 
enrichments for N-methyl carbons (δc 30.4 and δc 30.7) of peptide 1 and 1’  as observed in 
the 13C-NMR spectrum (Fig S30), indicating that the N-methyl groups are derived from S-
adenosyl-L-methionine (see 3.5.7 for experimental details). 
4.3.2.8 Proposed biosynthetic scheme for N-methyl-3-(3-furyl)-alanine  
Based on the results of the feeding experiments, a scheme for the biosynthesis of N-
methyl-3-(3-furyl)-alanine is proposed for the first time, clearly following the shikimate 
pathway (Fig 4-14). Concerning the sequence of steps and intermediate precursors 
involved, many questions remain open. Ring cleavage of a shikimate intermediate 
resulting in ring opening with subsequent cyclisation would lead to the formation of the 
furan moiety, as disclosed from biosynthetic studies for the dihyrdofuranacrylic acid 
moiety of reductiomycin.104 Introduction of the amino group, probably from glutamic acid 
catalyzed by a transaminase, would lead to the basic carbon skeleton of 3-(3-furyl)-
alanine.97 A methyl group is then transferred from S-adenosyl-L-methionine to the 
nitrogen, with the help of a methyltransferase, releasing S-adenosyl-L-homocysteine in 
the process.16 
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Fig 4-14. Postulated biosynthesis of N-methyl-3-(3-furyl)-alanine of peptide 1 and 1’. 
Biosynthetic/Metabolic origin of valine and leucine in peptide 1 and 1’ 
Both branched-chain amino acids, leucine and valine follow a similar biosynthesis from 
two pyruvate starter units with α-ketoisovalerate as an intermediate. The additional 
carbon for leucine is provided through an aldol condensation of α-ketoisovalerate with 
acetyl-CoA, followed by decarboxylation of the intermediate β-keto acid to give α-
ketoisocaproate. Lastly a pyridoxal phosphate (PLP)-dependent transamination with 
glutamate introduces the amino group to give valine and leucine.113  
The labeling patterns observed for valine and leucine after feeding [U-13C]glycerol, [1-
13C]glucose and [1-13C]sodium acetate is biosynthetically trivial, but validates the applied 
feeding protocols. Metabolic turnover of fed [U-13C]glycerol and [1-13C]glucose through 
the glycolytic pathway, provides [U-13C]pyruvate, [1,2-13C]acetyl-CoA, and [3-13C]pyruvate 
and [2-13C]acetyl-CoA, respectively. This is reflected in the observed labeling pattern for 
[U-13C]glycerol incorporation, where carbons of valine and leucine occurred as either 
enriched doublets, i.e. C-9/C-10, C-12/C-14 of leucine and C-25/C-26, C-27/C-28 of valine 
for peptide 1 and C-9/C-10, C-11/C-12 of valine and C-24/C-25 and C-27/C-29 of leucine 
for peptide 1’, due to the contribution of intact two-carbon units, or as enriched singlets, 
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i.e. C-11 and C-13 of leucine and C-29 of valine for peptide 1 and C-13 of valine and C-26 
and C-28 of leucine for peptide 1’, as a result of carbon rearrangements (Fig S28). For 
detailed chemical shifts and coupling constants see Table S2 and S3 for [U-13C]glycerol-
derived peptide 1 and 1’ respectively. This is in agreement with the labeling of C-10 (δc 
49.3), C-13 (δc 22.5) and C-14 (δc 23.2) of leucine and C-28 (δc 20.7) and C-29 (δc 18.4) of 
valine for peptide 1 and C-12 (δc 20.8) and C-13 (δc 18.4) of valine and C-25 (δc 49.1), C-28 
(δc 22.5) and C-29 (δc 23.3) of leucine for peptide 1’, after feeding [1-
13C]glucose (Fig S29). 
Furthermore, feeding [1-13C]sodium acetate resulted in enrichments at carbonyl carbon 
(Fig S31), i.e. C-9 (δc 172.9) of leucine for peptide 1 and C-24 (δc 172.5) of leucine for 
peptide 1’, from direct incorporation of fed [1-13C]sodium acetate (Fig 4-15).  
 
Fig 4-15. Observed labeling patterns for valine and leucine moieties of peptide 1 and 1’ after feeding 
13
C 
labeled precursors. Bold lines indicate 
13
C labeled isotopomers with directly adjacent 
13
C atoms. Dots 
indicate 
13
C enriched atoms. Balls indicate 
13
C labeled positions from [1-
13
C]sodium acetate.  
 
 
 
Results 
78 
 
Table 4-12. Results of feeding experiments for peptide 1. 
No. Fed precursor Enriched carbon atoms in peptide 1
1 
N-Me-FurAla Leu N-Me-Phe Val 
1 [1-
13
C]phenylalanine n.e. n.e. C-15 n.e. 
2 [U-
13
C]glycerol C-1/C-2/C-3,  
C-5/C-4/C-7,  
C-6 
C-9/C-10,  
C-12/C-14, 
C-11, C-13 
n.d. C-25/C-26, 
C-27/C-28,  
C-29  
3 [1-
13
C]glucose C-3, C-5 C-10, C-13, C-14 C-17, C-19, C-23 C-28, C-29 
4 [1-
13
C]sodium acetate n.e. C-9 n.e n.e 
5 [Me-
13
C]methionine  C-8 n.e. C-24 n.e 
n.e.: not enriched, n.d.: not detectable due to signal overlapping, 
1
 for structure see Fig 4-4 
Table 4-13. Results of feeding experiments for peptide 1’. 
No. Fed precursor Enriched carbon atoms in peptide 1’
1 
N-Me-FurAla Val N-Me-Phe Leu 
1 [1-
13
C]phenylalanine n.e. n.e. C-14 n.e. 
2 [U-
13
C]glycerol C-1/C-2/C-3,  
C-5/C-4/C-7, 
 C-6 
C-9/C-10,  
C-11/C-12, 
 C-13 
n.d. C-24/C-25, 
C-27/C-29,  
C-26, C-28  
3 [1-
13
C]glucose C-3, C-5 C-12, C-13 C-16, C-18, C-22 C-25, C-28, C-29 
4 [1-
13
C]sodium acetate n.e. n.e n.e C-24 
5 [Me-
13
C]methionine  C-8 n.e. C-23 n.e 
n.e.: not enriched, n.d.: not detectable due to signal overlapping, 
1
 for structure see Fig 4-4 
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4.3.3 Biosynthetic/Metabolic origin of marilone A and mariline B    
4.3.3.1 Labeling studies with [1-13C]sodium acetate  
Labeled marilone A and mariline B were isolated from a biomalt salt agar culture 
supplemented with [1-13C]sodium acetate following the previously described isolation 
scheme (see 3.5.6 for experimental details and Fig S2).83,84 Identity of the isolated 
marilone A and mariline B was confirmed using LC-MS, with molecular ion peaks at m/z 
345.2 [M+H]+ and m/z 388.5 [M+H]+ for marilone A and mariline B, respectively (Fig S40 
and S41).83,84 Additionally, the isotope pattern observed in the MS spectra indicated the 
incorporation of [1-13C]sodium acetate into the isolated metabolites. 13C-NMR spectra 
were analyzed by comparison with 13C-NMR spectra of previously reported unlabeled 
marilone A (Fig S32 and S33) and mariline B (Fig S34 and S35) from Stachylidium sp.83,84 
Chemical shift assignments were consistent with those previously reported (Table S4). 
Marilone A and mariline B showed enrichments for C-1, C-3, C-5 and C-7 of the basic 
skeleton, and C-1’, C-3’, C-5’and C-7’ of the geranyl side chain. Thus, alternate carbon 
atoms of marilone A and mariline B were found to incorporate intact acetate units. 
 
Fig 4-16. Observed labeling patterns for marilone A and mariline B after feeding [1-
13
C]sodium acetate. Balls 
indicate 
13
C enriched atoms.  
4.3.3.2 Labeling studies with [Me-13C]methionine  
It was not possible to isolate marilone A and mariline B from a [Me-13C]methionine fed 
biomalt salt agar culture and not much could be deduced from this experiment with 
respect to the polyketides biosynthesis (see 3.5.7 for experimental details). 
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4.3.3.3 Proposed biosynthetic scheme for marilone A and mariline B  
The observed labeling pattern for marilone A and mariline B after feeding [1-13C]sodium 
acetate suggests a total of four intact acetate units to be joined in a head-to-tail fashion 
forming a tetraketide chain to  outline the biosynthesis of the marilone A and mariline B 
basic carbon skeleton. Subsequently, cyclisation and methylation of this chain would 
afford an intermediate 3-methyl orsellinic acid derivative. Ring closure and formation of 
the lactone or lactam ring takes place to form the phthalide and phthalimidine skeleton, 
respectively. The nitrogen atom for the lactam ring of mariline B is probably derived from 
ethanolamine. Recently, the biomimetic synthesis of the phthalimidine core structure was 
carried out using ortho-formyl-arylketone which smoothly condenses with ethanolamine 
under mild conditions to yield the mariline B core structure, supporting this 
presumption.114 O-prenylation and O-methylation further decorates the basic carbon 
skeleton, with the help of a prenyltransferase and methyltransferase, respectively.  
The observed labeling pattern for the geranyl side chain of marilone A and mariline B 
after feeding [1-13C]sodium acetate, confirms it’s mevalonate origin. Through 
condensation of three units of acetyl CoA, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) is 
formed, which is further reduced to mevalonic acid. Mevalonic acid is then transformed 
into a phosphorylated isoprene unit (isopentenyl diphosphate), the basic building unit of 
terpenes. Isopentenyl diphosphate (IPP) is isomerized to give dimethylallyl diphosphate 
(DMAPP). Combination of DMAPP and IPP would give the geranyl diphosphate (GPP) side 
chain (Fig 4-17).97  
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Fig 4-17. Proposed biosynthetic scheme for marilone A and mariline B. 
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4.3.4 Discussion 
Peptide 1 and 1’ 
Feeding experiments with [U-13C]glycerol, [1-13C]glucose, [1-13C]phenylalanine, [1-
13C]sodium acetate and [Me-13C]methionine in Stachylidium sp. ascertained the 
biosynthetic origin of the peptide building blocks, i.e. valine, leucine, phenylalanine and 3-
(3-furyl)-alanine (Fig 4-18). Labeling patterns observed after feeding both [U-13C]glycerol 
and [1-13C]glucose were in accordance with previously reported labeling patterns for 
shikimate-derived metabolites.108,112,115 The involvement of shikimic acid as a biosynthetic 
intermediate could not be verified unambiguously, nonetheless the incorporation 
patterns for both [U-13C]glycerol and [1-13C]glucose into peptide 1 and 1’ give clear 
evidence for the involvement of a shikimate-related pathway in the biosynthesis of 3-(3-
furyl)-alanine. The shikimate pathway is thus believed to account for all the carbon atoms 
of the N-methyl-3-(3-furyl)-alanine, apart from the N-methyl group, which is provided by 
the methyl group of methionine. The remaining amino acids are derived from standard 
building blocks as described in literature.97,113  
 
Fig 4-18. Biosynthetic origin of the carbons in peptide 1 and 1’. 
13
C labeling patterns from the incorporation 
of [U-
13
C]glycerol, [1-
13
C]phenylalanine and [Me-
13
C]methionine. 
Exogenous supply of phenylalanine, both labeled and unlabeled, resulted in an increase in 
the amount of isolated peptides showing a phenylalanine residue, attributed to an 
increased supply of the precursor amino acid. This is normally encountered in precursor-
directed biosynthetic studies, a strategy frequently exploited to boost the production of a 
target metabolite.116,117 At the same time, this resulted in a decrease in the amounts of 
isolated peptides featuring a 3-(3-furyl)-alanine, presumably as a result of feedback 
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inhibition (Fig S36). This indicates the biosynthetic relationship between both 
phenylalanine and 3-(3-furyl)-alanine. At the same time, failure of incorporation of 
labeled phenylalanine into 3-(3-furyl)-alanine indicated that phenylalanine is not an 
intermediate in the biosynthesis of 3-(3-furyl)-alanine as hypothesized earlier, but rather 
an earlier intermediate in the shikimate pathway must provide the carbon units for the 
biosynthesis of 3-(3-furyl)-alanine.  
Unlike biosynthetic results reported for the reductiomycin, two distinct labeling patterns 
for the dihydrofuranacrylic acid moiety of reductiomycin were observed after feeding [U-
13C]glycerol (Fig 4-19). In our experiments a single labeling pattern was observed for 3-(3-
furyl)-alanine after feeding [U-13C]glycerol. Presence of two labeling patterns for the 
dihydrofuranacrylic acid moiety of reductiomycin was justified by the involvement of a 
symmetric intermediate, in this case 4-hydroxybenzoic acid, undergoing two plausible 
ring cleavage reactions leading to the dihydrofuranacrylic acid moiety. This was confirmed 
with feeding studies using labeled 4-hydroxybenzoic acid.104 The involvement of 4-
hydroxybenzoic acid as a putative intermediate in the biosynthesis of 3-(3-furyl)-alanine 
was thus not plausible and was ruled out. This is also mirrored in the failure to detect 
incorporation of a fluoro-substituted-4-hydroxybenzoic acid in peptide 1 and 1’ (Fig 
S38(D)).  
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Fig 4-19. Labeling and 
13
C-
13
C coupling pattern in the dihydrofuranacrylic acid moiety of reductiomycin 
derived from [U-
13
C]glycerol according to literature.
104
 Observed labeling pattern for 3-(3-furyl)-alanine 
after feeding [U-
13
C]glycerol. Bold lines indicate 
13
C labeled isotopomers with directly adjacent 
13
C atoms. 
Dots indicate 
13
C enriched atoms. 
Biosynthesis of a furan moiety is generally believed to proceed through a mixed acetate-
glycerol pathway, through condensation of dihydroxyacetone and a β-ketothioester as 
seen in methylenomycin furans and (propenyl-3-furanyl)carbonyl α-L-
rhamnopyranoside.118,119,120 This could not be seen as the case here, as fed [U-13C]glycerol 
was not observed to label C-3/C-4/C-7 of 3-(3-furyl)-alanine, and feeding [1-
13C]sodium 
acetate resulted in high background, non-specific labeling of 3-(3-furyl)-alanine explained 
by metabolic turnover of [1-13C]sodium acetate during primary metabolism. Accordingly, 
a mixed acetate-glycerol biosynthetic pathway being involved in the biosynthesis of 3-(3-
furyl)-alanine is ruled out (Fig 4-20). 
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Fig 4-20. Observed incorporation patterns for compounds of mixed acetate-glycerol biosynthesis, i.e 
methylenomycin furan and acyl α-L-rhamnopyranoside, adopted from literature.
119,120
 Hypothetical and 
observed incorporation patterns for 3-(3-furyl)-alanine with glycerol and sodium acetate as precursors, 
excluding the involvement of a mixed acetate-glycerol pathway in the biosynthesis. Bold lines indicate 
13
C-
labeled isotopomers with directly adjacent 
13
C atoms and dots indicate 
13
C enriched atoms arising from [U-
13
C]glycerol. Balls indicate 
13
C labeled positions from [1-
13
C]sodium acetate.  
After feeding [U-13C]glycerol all carbons of 3-(3-furyl)-alanine occurred either as doublet 
of doublets, i.e. C-1/C-2/C-3 and C-5/C-4/C-7, or as a singlet, i.e. C-6, eliminating the 
contribution of two-carbon units, recognized as coupled doublets in 13C-NMR, from 
acetyl-CoA arising from metabolism of glycerol through glycolysis. This was further 
confirmed through feeding studies with [1-13C]sodium acetate, that ruled out the 
involvement of the polyketide pathway. Thus, the contribution of the mevalonate 
pathway, incorporating three acetyl-CoA building blocks, in the biosynthesis of 3-(3-furyl)-
alanine is excluded.97 Moreover, the observed labeling pattern after feeding [1-
13C]glucose does not imply the contribution of isopentenyl diphosphate (IPP), neither 
through the mevalonate (MVA) nor the methylerythritol phosphate pathway (MEP), in 
the formation of the furan ring of the 3-(3-furyl)-alanine (Fig 4-21).121  
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Fig 4-21. Exclusion of the involvement of a terpenoid biosynthetic pathway for 3-(3-furyl)-alanine. 
Hypothetical formation of a furan moiety using isopentenyl diphosphate (IPP) and dimethylallyl 
diphosphate (DMAPP) via the mevalonic acid (MVA) and methylerythritol phosphate (MEP) pathways and 
observed labeling pattern for 3-(3-furyl)-alanine from [1-
13
C]glucose feeding experiment. Dots indicate 
13
C 
enriched positions arising from [1-
13
C]glucose. Adopted from literature.
121
 
Cyclisation of sedoheptulose-7-phosphate, an intermediate of the pentose phosphate 
pathway, is not considered relevant to the biosynthesis of the carbon skeleton of 3-(3-
furyl)-alanine. A sedoheptulose biosynthetic pathway, involved in the biosynthesis of the 
C7N moiety of the carba sugar acarbose and the antibiotic validamycin, gives a unique C2-
C2-C3 labeling pattern, as opposed to the C3-C4, i.e. phosphoenolpyruvate-erythrose-4-
phosphate, pattern for a shikimate pathway (Fig 4-22).122 
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Fig 4-22. Biosynthetic origin of the C7N unit of acarbose and validamycin A from sedoheptulose-7-
phosphate based on incorporation patterns after feeding [1-
13
C]glucose and [U-
13
C]glycerol.
122
 Observed 
labeling pattern for 3-(3-furyl)-alanine from [1-
13
C]glucose and [U-
13
C]glycerol feeding experiments 
excluding the involvement of sedoheptulose-7-phosphate in the biosynthesis. Bold lines indicate 
13
C labeled 
isotopomers with directly adjacent 
13
C atoms and black dots indicate 
13
C enriched atoms arising from [U-
13
C]glycerol. Red dots indicate 
13
C enriched atoms arising from [1-
13
C]glucose. 
Polyketides  
Due to the small culture size of 1.5 L biomalt salt agar medium, and the low amounts of 
polyketides, i.e. 0.26 – 0.5 mg L-1, produced by the Stachylidium sp., as previously noted 
from the preliminary experiments, it was infeasible to isolate the whole array of 
marilones and marilines previously reported.83,84 Nevertheless, we succeeded in isolating 
labeled marilone A and mariline B, a representative of each compound class, i.e. 
phthalide and phthalimidine, respectively. Both showed very similar enriched 13C-NMR 
spectra, indicating their analogous biosynthetic origin. For the basic nucleus of marilone A 
and mariline B, four intact acetate units were incorporated, joined in a head-to-tail 
fashion, to form a tetraketide chain that undergoes subsequent cyclisation to form the 
aromatic ring, as encountered in other phthalide metabolites, i.e. mycophenolic acid,98 
nidulol and silvaticol.99 The folding of the tetraketide chain probably follows the mode F, 
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which is typical for fungal producers of fused-ring aromatic structures.123 The labeling 
pattern observed for the geranyl side chain, evidenced its origin through the mevalonate 
pathway as seen in mycophenolic acid.98 It is known that fungi and animals exclusively use 
the mevalonate pathway for the synthesis of their terpenoid units.124 Marilone A and 
mariline B are thus considered to be of mixed biosynthetic origin, featuring both a 
polyketide and terpenoid part. For the starter unit involved in the biosynthesis, 
accounting for the unusual methyl substituent at C-8, this could not be unequivocally 
deduced from the feeding study with [1-13C]sodium acetate. Yet, the efficient 
incorporation of an acetate unit at C-7 as seen for both marilone A and mariline B, favors 
a methylated acetate starter unit over a propionate unit. If enrichment of C-7 was due to 
metabolic turnover of [1-13C]acetate to [1-13C]propionate (Fig 4-23), we would have 
expected a less intense signal for C-7 as compared to other carbons, i.e. C-1, C-3 and C-5, 
of the basic carbon skeleton. Definite proof for this speculation could only be confirmed 
by further feeding studies employing labeled precursors, such as propionate or 
methionine, or through genetic investigations.  
 
Fig 4-23. Metabolism of [1-
13
C]acetate into [1-
13
C]propionate.
125
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4.4 Biological activity of peptide 1 and 1’ on galanin receptors (GalR) 
Peptide 1 and 1’ (Fig 4-4) displayed selective in-vitro agonist activity to galanin receptor 
subtype 1 (GalR1), in a pilot label-free dynamic mass redistribution (DMR) assay, using 
recombinant human embryonic kidney (HEK) cells stably expressing GalR1 (see 3.6.2 for 
experimental details).88,89 When applied in a micromolar range (10-100 µM), peptide 1 
and 1’ showed a concentration-dependant increase of DMR recordings as compared to 
native HEK cells, lacking GalR1 receptors. Preincubation of the cells with pertussis toxin 
(PTX), a specific inhibitor of the GalR1-coupled G protein αi subunit, followed by addition 
of a mixture of peptide 1 and 1’, resulted in a reduction of the DMR recordings nearly to 
the niveau of native HEK cells (Fig 4-24). These results clearly reveal the association of an 
increased DMR with an activation of the GalR1 by peptide 1 and 1’, and are in accordance 
with the in-vivo anti-convulsive activity data of endolide A (Fig 4-2), a cyclic tetrapeptide 
formerly isolated from the same fungal strain.96 
 
 
Fig 4-24. DMR-profiles of non-recombinant (A) and GalR1 stably expressing (B,C) HEK293 cells. Stimulation 
of the cells with different concentrations of peptide 1 and 1’ results in a concentration-dependent increase 
in wavelength shift for the recombinant cell line (B), which is absent in native HEK cells (A). Pre-incubation 
of the recombinant cells with pertussis toxin (PTX, 200 ng ml
-1
) causes a significant blunting of the DMR 
signals (C) in comparison to PTX-untreated cells (B), resembling the DMR profile of the control cells lacking 
the receptor (A). Assays were performed by Dr. Harald Dargatz, WG Kostenis, Institute for Pharmaceutical 
Biology, University of Bonn.
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5. General Discussion 
5.1 Chemical diversity of Stachylidium sp. secondary metabolites 
Although the Stachylidium sp. strain has been chemically investigated before in our 
group, new metabolites could be still isolated during the current study. This delineates 
the impressive biosynthetic capabilities of this fungal strain as illustrated in the plethora 
of secondary metabolite classes reported so far. Compound classes isolated range from 
polyketides,83,84 to O-prenylated tyrosine-derived compounds,85 to furyl derivatives,126 
and of special interest the novel peptides characterized in the current study. These 
peptides are constructed from a varying combination of four basic building blocks, two 
branched chain amino acids, i.e. L-valine, L-leucine, and two aromatic amino acids, i.e. L-
phenylalanine and L-3-(3-furyl)-alanine. Structural similarities between the isolated 
peptides are quite remarkable. They only exhibit slight differences in terms of the 
constituent amino acids. The individual peptides differ also in terms of N-methyl 
substituents and amino acid sequence. Their very closely related structures made their 
isolation and subsequent characterization most challenging. The novel peptides and 
diketopiperazines isolated in this study (Fig 4-3) further expand the range of compound 
classes metabolically produced by the here targeted Stachylidium sp. strain. Two 
previously reported thiodiketopiperazines (Fig 4-5), i.e. bisdethiobis(methylthio)-
acetylaranotin (BDA) and bisdethiobis(methylthio)-acetylapoaranotin (BDAA),102,155 were 
also isolated from a phenylalanine supplemented liquid biomalt culture medium.  
5.2 Novel cyclic peptides and the putative non-ribosomal peptide assembly line 
The novel isolated peptides are proposed to be synthesized by the non-ribosomal peptide 
biosynthetic machinery (NRPS). This is supported by the structural architecture of the 
peptides, incorporating unusual amino acid motifs with additional N-methylation and 
cyclization. These features are all privileged attributes frequently encountered in non-
ribosomal peptides. Contradictory to the wide array of produced cyclic peptides in the 
Stachylidium sp., a single NRPS is believed to be involved in the biosynthesis of these 
structures. This was previously observed for structurally related peptides from fungal 
species, e.g. 25 naturally occuring cyclosporins97 and as much as 29 isolated enniatins.34 
This is credited to the flexibility of NRPS systems being able to incorporate varying 
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building blocks. Rationalized by the microheterogenicity of the involved adenylation 
domains accepting different building blocks, e.g. surfactin synthetase adenylation domain 
is capable of activating L-leucine, L-valine and L-isoleucine.127 Promiscuity of fungal NRPS 
to alternative amino acid residues is generally encountered, and has been exploited with 
the aim to obtain new analogues of naturally produced peptides luckily with better 
activity and/or selectivity.128,129,130 At the same time this could provide additional 
information for biosynthetic studies.110 Feeding experiments using other amino acids, 
such as alanine, glycine, proline, tryptophan and serine, did not result in the production of 
newer analogues. Therefore, it is believed that enzymes involved in the biosynthesis of 
those peptides are specific for their amino acid residues, i.e. valine, leucine, 
phenylalanine and 3-(3-furyl)-alanine. Here the Stachylidium sp. NRPS machinery 
generated a natural combinatorial/chemical library of cyclopeptides. Using only a small 
number of basic building blocks and applying the LEGO principle a wide array of 
metabolites were formed.131 Shuffling of those four amino acids in four different 
positions, we could imagine a total of 256 different peptides to be produced, of which 
only a small fraction had been isolated in this study. In fact some of the peptides were 
predominately produced over other peptides, pointing towards the preferred activation 
of certain amino acids by the adenylation domains. 
5.3 Biosynthetic considerations 
5.3.1 General considerations of feeding protocols  
The contribution of classical isotope tracer experiments in the study of mechanisms 
involved in the assembly of secondary metabolites cannot be underestimated.105,106,110 In 
spite of the growing trend to apply molecular genetic techniques for biosynthetic studies 
on secondary metabolites, classical isotope tracer experiments are still regarded as an 
indispensable tool in exploring the biogenesis of secondary metabolites basic framework 
and revealing convergent pathways in different species.123,132,133 Information gained from 
the incorporation of isotopically labeled precursors could provide the starting point for 
further biosynthetic studies and frequently both approaches are applied 
synchronously.112,108,134,135,136 
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Regardless of the general hurdles encountered in biosynthetic feeding studies in marine 
organisms, as outlined earlier (see 4.3.1), and the non-reproducibility of biosynthetic 
experiments with different precursors, we established here a successful feeding protocol 
for the precursors of interest on solid biomalt salt media. Biosynthetic feeding 
approaches should generally be customized with regard to the nature of the 
microorganism, the prospective metabolite of interest and the fed precursor. The here 
implemented feeding protocol was carefully planned according to the valuable input 
collected from the preliminary experiments. We were confined to the use of solid media, 
not regarded as the medium of choice for biosynthetic feeding studies, since only there 
the metabolites of interest are efficiently produced. Few biosynthetic feeding studies use 
solid media,137,138,139,140,141 compared to the use of liquid shake media.98,99,104,112,115,118,136 
The amount of precursor fed depends on its nature and the target metabolite 
incorporating it. A general carbon source precursor such as glucose or glycerol has to be 
added in higher quantities compared to a more specific precursor such as phenylalanine, 
shikimic acid or methionine. This is largely due to the universality of the former, being 
involved in several biosynthetic pathways. At the same time this of course helps in 
defining the involved biosynthetic pathway, from the resulting 13C-labeled positions in the 
target metabolite. High costs of labeled precursors also dictated the volume of culture 
media used, limited to 0.5 to 1.5 liter media, which made isolation of the target 
metabolites most challenging. A multiple feeding protocol as applied in this study ensured 
a steady supply of precursors during metabolite biosynthesis, but care had to be taken in 
maintaining aseptic conditions throughout the cultivation period. The long cultivation 
period of 30 and 60 days, due to the slow-growing nature of the Stachylidium sp. strain, 
meant unavoidable lengthy waiting periods. 
In the end, it was possible to isolate the compounds of interest in 13C-labeled form, whose 
detailed analysis using NMR and mass spectrometric techniques unveiled the biosynthetic 
origin of those target metabolites, i.e. the peptides and polyketides (see 4.3).  
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5.3.2 Biosynthesis of the cyclic peptides: The shikimate pathway as a source of 
secondary metabolites 
Our results confirm the origin of the amino acid building blocks of the cyclic peptides from 
the Stachylidium sp.. Information gained from this study, concluded the involvement of 
the shikimate pathway in the biosynthesis of the non-proteinogenic amino acid N-methyl-
3-(3-furyl)-alanine, not frequently encountered in nature, and whose biosynthetic origin 
was never revealed before. The opening line in the shikimate pathway involves the 
condensation of phosphoenolpyruvate, from glycolysis, and erythrose-4-phosphate, from 
the pentose phosphate pathway, to give 3-deoxy-D-arabino-heptulosonate-7-phosphate 
(DAHP), catalysed by DAHP synthase. Elimination of phosphoric acid followed by an 
intramolecular aldol reaction gives the first carbocycle intermediate 3-dehydroquinic acid, 
which further undergoes dehydration and reduction to give shikimic acid, the first 
significant intermediate from which the shikimate pathway got its name. This is then 
followed by several metabolic steps that end with the synthesis of another key 
intermediate, chorismic acid, which has incorporated an additional phosphoenolpyruvate. 
Chorismic acid then serves as the starting point for the synthesis of the aromatic amino 
acids (AAA), i.e. phenylalanine, tyrosine and tryptophan.97  
The shikimate pathway is one of the important biosynthetic pathways in microorganisms 
and plants, extensively studied to reveal the pathway reactions and involved 
enzymology.142,143 In addition to its significance in the biosynthesis of the aromatic amino 
acids, as part of the primary metabolism, it is involved in the biosynthesis of a variety of 
secondary metabolites. It is generally accepted that secondary metabolites are not 
biosynthesized de novo and are dependent on the input of primary metabolism to 
provide the biosynthetic machinery with building blocks. These primary metabolites are 
thus modified in secondary metabolism. This way microorganisms and plants produce a 
wide variety of specialized compounds essential for their inherent needs, exemplified in 
the mycotoxins, pigments and antibiotics.144 Some of these secondary metabolites are 
being directly derived from modification of the final end products of the shikimate 
pathway, e.g. ephedra alkaloids originally isolated from Ephedra sp. have their 
biosynthetic origin from phenylalanine145 and ergot alkaloids whose basic ergoline 
skeleton is derived from tryptophan (Fig 5-1).58 Others are derived from branching points 
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alongside the shikimate biosynthetic route, e.g. the antibiotic chloramphenicol (Fig 5-1), 
originally isolated from the bacterium Streptomyces venezuelae, originates in the 
shikimate pathway via 4-amino-4-deoxy-chorismic acid,146 and the aromatic m-C7N unit of 
the mitomycin and ansamycin antibiotics, e.g. rifamycin, is derived from the starter unit 
3-amino-5-hydroxybenzoic acid (AHBA) originating from the shikimate pathway (Fig 5-
2).147 These shikimate derived secondary metabolites are already important active 
pharmaceutical ingredients (APIs) used as drugs nowadays. Shikimic acid itself is used as 
the starting material for the industrial synthesis of oseltamivir (Tamiflu®), an antiviral 
drug used against influenza (Fig 5-3).97  
 
Fig 5-1. Secondary metabolites of shikimate origin.    
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Fig 5-2. Structures of m-C7N unit containing natural antibiotics derived from the shikimate pathway. 
 
Fig 5-3. Synthetic drug derived from shikimic acid. 
Additionally, the shikimate pathway accounts for the unique chemistry realized in several 
non-aromatic metabolites such as the fused bicyclic β-lactone in vibralactone isolated 
from the basidomycete fungus Boreostereum vibrans,108 the tricyclic acetal-lactone 
structure of echinosporin isolated from Streptomyces erythraceus,115 or the 
dihydrofuranacrylic acid moiety of reductiomycin (Fig 5-4).104 It thus comes as no surprise 
that the shikimate pathway is responsible for the biosynthesis of the unprecedented 
heterocyclic aromatic amino acid 3-(3-furyl)-alanine. 
 
Fig 5-4. Secondary metabolites with unique chemistry derived from the microbial shikimate pathway. 
5.3.3 Phthalides and phthalimidines biosynthesis 
A second focus of this study yielded fruitful insights concerning the biosynthesis of the 
polyketide metabolites of the Stachylidium sp.. The educated guess that the phthalide 
and phthalimidine basic skeletons are biosynthetically related was confirmed based on 
the similar incorporation patterns observed after feeding [1-13C]sodium acetate. We 
could not yet fully ascertain the starter unit accountable for the unique methyl 
substituent at C-8 (Fig 4-5). Nevertheless, our results propose a methylated acetate 
starter unit. Yet we cannot exclude that both starter units, i.e. methylated acetate or 
alternatively propionate, could be involved as seen in the biosynthesis of the mycotoxin 
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aurovertin B.148 The phthalide and phthalimidine aromatic nucleus is proposed to be 
biosynthesized from a tetraketide chain with a 3-methyl orsellinic acid derivative as an 
intermediate. Biosynthetic modifications of derivatives of the archetypical tetraketide 
orsellinic acid are seen in the production of several known fungal metabolites. These 
include the toluquinonoid nucleus of fumigatin and spinulosin, the 7-membered aromatic 
tropolone ring in puberulic and stipitatic acid, and the phthalide skeleton of gladiolic acid 
and mycophenolic acid (Fig 5-5).10  
 
Fig 5-5. Fungal tetraketide metabolites. Bold lines indicate intact acetate units incorporated. Dots indicate 
enriched carbons after cleavage or rearrangement of acetate units. 
5.4 Pharmacological relevance of isolated peptides 
One of the major goals of natural product research, including this study, is the 
characterization of secondary metabolites that could be used as drug leads. The interest 
in peptide drug scaffolds is currently on the rise, and peptides inherent characteristics 
nominates them as interaction partners for biological targets, e.g. pasireotide (Signifor®) 
a somatostatin receptor agonist indicated for Cushing’s disease, carfilzomib (Kyprolis®) a 
chymotrypsin-like protease inhibitor for treatment of multiple myeloma, linaclotide 
(Constella®) a guanylate cyclase receptor agonist indicated for chronic idiopathic 
constipation and irritable bowel syndrome (IBS) and monomethyl auristatin E (vedotin) a 
neoplastic agent linked to a monoclonal antibody, are to name just a few peptide-based 
drugs approved in the last 5 years (Fig 5-6).2,149   
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Fig 5-6. Peptide-based drugs approved in the last 5 years.  
The small amounts of novel peptides isolated in this study impeded the possibility of 
performing comprehensive bioactivity studies for the full spectrum of peptides. The 
promising results obtained for peptide 1 and 1’ on the galanin receptor subtype-1 (GalR1) 
stimulate further studies using the full array of isolated peptides. Galanin receptors are 
members of the G protein-coupled receptors (GPCR), a large group of peptide drug 
targets with around 39% of peptides in clinical trials targeting GPCRs.2 Up to now three 
galanin receptor subtypes have been recognized, i.e. GalR1 - 3, differentially expressed 
throughout the peripheral and central nervous systems, as well as the endocrine 
system.150 The ubiquitous distribution and association of the galanin receptor subtypes in 
various physiological and pathological states makes them interesting drug targets, being 
addressed by either agonists or antagonists.151 GalR1 and GalR2 seem to play a role in 
seizures, with GalR1 being responsible for seizure induction and GalR2 in maintaining and 
controlling the strength of the seizure. GalR3 showed a more limited distribution with less 
defined roles.152 Observing that galanin, an endogenous 29/30 amino acid neuropeptide, 
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was extensively up-regulated during epileptic seizures as well as in Alzehimer’s disease, 
proposed targeting the galanin system for the treatment of neuronal damage. Galanin 
analogues have been synthesized to overcome the poor pharmacokinetic properties, i.e. 
poor bioavailability and poor blood brain barrier penetration of endogenous galanin. They 
include chimeric peptidic ligands such as M15 and M35 (Table 5-1), and other ligands, like 
galnon and galmic acid (Fig 5-7), acting as either agonists or antagonists to one or more of 
the galanin receptor subtypes.152  
Table 5-1. Amino acid sequence of human galanin and peptide ligands, i.e. M15 and M35 (adopted from 
literature).
150
  
  Sequence 
Human galanin  GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS 
M15 (antagonist) GWTLNSAGYLLGPQQFFGLM-amide 
M35 (antagonist) GWTLNSAGYLLGPPPGFSPFR-amide 
 
 
Fig 5-7. Galanin receptor ligands. 
Despite the number of available galanin receptor ligands,150 the demand for receptor sub-
type selective ligands is on-going, whether as possible therapeutics or as a tool for gaining 
a deeper understanding of the galanin receptor system. The current study shows that the 
marine environment, in particular the scantly explored marine fungus Stachylidium sp., 
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could be a source for such ligands on galanin receptors (Fig 4-24). And the natural 
combinatorial/chemical library of microheterogeneous peptides isolated so far could be 
employed for further biological testing to obtain more selective and potent ligands to the 
galanin receptors and subsequently the identification of the chemically simplest scaffold 
that maintains the desired biological activity. At the same time, a deeper understanding 
of structure activity relationships has to be sought.  
5.5 Future directions and concluding remarks 
The current study highlighted the biosynthetic potential of this fungal strain, although 
focusing on a single culture medium, i.e. biomalt salt agar medium. The use of other solid 
and liquid culture media, i.e. the OSMAC approach (One Strain Many Compounds), could 
probably lead to the production of more metabolites with intriguing structural features 
and promising biological activity.153 
The inclusion of fluoro-containing amino acids, i.e. 2-fluoro-phenylalanine and 3-fluoro-
phenylalanine (see 4.3.2.5), into the peptide architecture opens up possibilities for the 
production of a variety of peptide analogues. These could expand the peptide assortment 
used for biological testing.  Halogenated natural product derivatives, particularly 
fluorinated ones, are of special interest. Several drugs available on the market contain a 
fluorine substitution, the earliest being fluorouracil, an antineoplastic drug, as well as the 
antidepressant drug fluoxetine, and the macrolide antibiotic fluorithromycin.154 A fluorine 
substitution generally improves the pharmacological properties of a compound, in terms 
of improved metabolic stability, bioavailability and receptor binding.111 It is thus 
anticipated that the new fluorinated peptide analogues would show superior biological 
activity. Moreover, further precursors should be tested. Additionally, the accumulation of 
peptides incorporating phenylalanine after supplementing the cultivation medium with 
this amino acid as observed in our feeding studies is a practical strategy that could be 
employed to stimulate the production of metabolites of interest.116,117 After feeding the 
relevant precursors, the metabolites of interest could be isolated in bigger amounts, and 
then be used for exhaustive biological testing.  
It could not be ascertained whether the isolated epipolythiodioxopiperazines, i.e. BDA 
and BDAA, from a liquid biomalt salt culture medium supplemented with phenylalanine, 
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are normally produced by the fungus but went unnoticed from our initial isolation or are 
strictly produced after addition of phenylalanine, a known precursor of this class of 
compounds.103 It could still be concluded that the required gene for biosynthesis exists in 
the fungus and addition of the precursor probably provoked the fungal biosynthetic 
machinery to produce them. This speculation requires further studies and the prospect of 
obtaining other compounds belonging to this class is plausible. BDA and BDAA did not 
exhibit any biological activity when tested for antimicrobial activity in agar-diffusion 
assays (see 4.3.1). This coincides with previous studies that reported their minimal 
biological activity,155 apart from a growth inhibitory activity towards Mycobacterium 
tuberculosis,156 when compared to their disulfide bridge containing counterparts, i.e. 
acetylaranotin and acetylapoaranotin. The disulfide bridge is thus hypothesized to 
mediate biological activity and molecular toxicity of fungal 
epipolythiodioxopiperazines.103 
Our continuous trials to purify peptides featuring positional isomers, i.e peptide 1 and 1’, 
peptide 5 and 5’, peptide 6 and 6’, peptide 7 and 7’, where unavailing. This necessitates 
the ongoing development in HPLC stationary phase properties and modified mobile phase 
systems for the selective separation of peptides, a compound class gaining increasing 
attention lately.157,158    
Overall, the Stachylidium sp. is believed to be a talented fungal strain, whose biosynthetic 
capabilities have not yet been given its full due. This study is a sequel to the ongoing 
efforts undertaken to unravel its biosynthetic potential, with special emphasis on the 
biogenesis of the novel isolated peptides and polyketides. With regards to the isolated 
peptides, still there is an information gap on the underlying biosynthetic mechanisms 
involved in converting the shikimate intermediate into the 3-(3-furyl)-alanine. Further 
study of this process is merited as it should contribute to the full elucidation of this rare 
amino acid biosynthesis in Stachylidium sp. and probably in other microorganisms 
incorporating the same amino acid.68,74 
Much progress has been made to study fungal genomes.159 A single fungal genome 
encoding several biosynthetic enzymes is capable of providing us with a plethora of 
secondary metabolite classes. Several web-based software tools, such as SMURF 
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customized for fungal genomes, have been built for easy mapping of fungal genome 
clusters.160 With the help of genomic approaches, exploring the Stachylidium sp. 
secondary metabolome will reveal details of the assembly of the amino acid building 
blocks in the peptides and the starter unit involved in the polyketide metabolites. 
Furthermore, genetic manipulation of these assembly lines could maximize the chemical 
diversity of the produced metabolites.116       
It is hoped that the results presented here will elicit further studies in exploring this 
unique fungal strain more extensively, on both the chemical and genetic level. 
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6. Summary 
The fungal kingdom has made considerable contributions to the production of peptide 
secondary metabolites, many of them with therapeutic potential, e.g. the 
immunosuppressant cyclosporine and the antifungal echinocandins.    
The detailed investigation of the marine-derived fungus Stachylidium sp. was the main 
purpose of this research, which focused on the isolation, structural elucidation and 
biosynthesis of novel cyclic peptides. From a fungal culture on biomalt agar medium 
supplemented with sea salt, we succeeded in isolating and characterizing a family of 
novel structurally related peptides (Fig 6-1). Structural elucidation of the isolated peptides 
was achieved using 1D and 2D NMR spectroscopic analysis along with high-resolution 
mass spectrometry. The absolute configuration of the amino acid building blocks was 
assigned as L-configuration using advanced Marfey’s method and X-ray crystallography. 
The four amino acids, i.e. L-valine, L-leucine, L-phenylalanine and L-3-(3-furyl)-alanine 
form the basis of the isolated peptides. Structural similarities between the isolated 
peptides are quite remarkable. They only exhibit slight differences in terms of the 
constituent amino acids. The individual peptides differ also in terms of N-methyl 
substituents and amino acid sequence. Their very closely related structures made their 
isolation and subsequent characterization most challenging.  
The cyclic nature and N-methylation of the isolated peptides, as shared with other fungal 
peptides, implied their inherent potential as interesting drug scaffolds. The positional 
isomers peptide 1 and 1’ were tested on galanin receptors, in a concentration range 10-
100 µM, and displayed a concentration-dependant selective agonist activity towards the 
galanin 1 receptor subtype (GalR1). This nominates them as potential ligands for 
therapeutic applications or as a tool for studying the galanin receptor system. 
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Fig 6-1. Structures of the isolated cyclic peptides. 
A most intriguing feature of some of the isolated peptides was the incorporation of the 
rarely encountered amino acid 3-(3-furyl)-alanine, to date only reported in the 
heptapeptides rhizonin A and B and the pentapeptide bingchamide B. Due to the novel 
nature of this building block, the current study set out to study its metabolic origin. 
Biosynthetic studies employing classical isotope tracer experiments revealed the 
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shikimate origin of this rare amino acid, along with confirming the metabolic origin of the 
other proteinogenic amino acids, with the N-methyl group being derived from methionine 
(Fig 6-2, Fig 6-3).  
 
Fig 6-2. Origin of the carbon atoms of peptide 1 and 1’ as implied from results of feeding experiments. 
 
Fig 6-3. Postulated biosynthesis of N-methyl-3-(3-furyl)alanine as proposed from the analysis of peptide 1 
and 1’ after classical isotope experiments using labeled precursors including [1-
13
C]phenylalanine, [U-
13
C]glycerol, [1-
13
C]glucose and [Me-
13
C]methionine. 
Concerning the biosynthesis of the marilone A and mariline B, phthalide and 
phthalimidine metabolites previously reported from this fungal strain, labeling studies 
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with [1-13C]sodium acetate were undertaken. Their biosynthesis involves a polyketide and 
mevalonate mixed pathway (Fig 6-4).  
 
Fig 6-4. Origin of the carbon atoms of marilone A and mariline B as implied from results of the feeding 
experiment using [1-
13
C]sodium acetate. 
Overall, these results emphasize the outstanding biosynthetic potential of the here 
investigated Stachylidium sp.. It displays exceptional competence in employing various 
metabolic pathways, through which a diverse array of secondary metabolites are 
produced. Consequently, the novel isolated metabolites characterized in this study could 
serve as lead structures for drug discovery. Furthermore, insights gained from the here 
applied classical isotopic tracer experiments will serve as the basis for future 
investigations employing genetic and enzymatic approaches. Sequencing of the 
Stachylidium sp. genome and identifying the biosynthetic gene cluster associated with the 
production of those unique fungal metabolites would lead to a conclusion concerning still 
unresolved ambiguity.
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8. Appendix 
8.1 Metabolites isolated during this study 
No.  
1 Peptide 1: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-leucyl, (N-methyl-(L)-
phenylalanyl), (L)-valinyl] 
Peptide 1’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-
phenylalanyl), (L)-leucyl] 
2 Peptide 2 (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-furylalanyl, N-methyl-(L)-
phenylalanyl, (L)-valinyl] 
3 Peptide 3 (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-phenylalanyl, N-methyl-(L)-
phenylalanyl, (L)-valinyl] 
4 Peptide 4 (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)- valinyl, (N-methyl-(L)-3-
(3-furyl)-alanyl), (L)- phenylalanyl] 
5 Peptide 5: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-3-(3-furyl)-alanyl, (N-
methyl-(L)-phenylalanyl), (L)-valinyl] 
Peptide 5’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-
phenylalanyl), (L)-3-(3-furyl)-alanyl] 
6 Peptide 6: (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-leucyl, N-methyl-(L)-leucyl, (L)-
valinyl] 
Peptide 6’: (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-valinyl, N-methyl-(L)-leucyl, 
(L)-leucyl] 
7 Peptide 7: (-)-Cyclo-[N-methyl-(L)-3-(3-furyl)-alanyl, (L)-leucyl, N-methyl-(L)-leucyl, 
(L)-valinyl] 
Peptide 7’: (-)-Cyclo-[N-methyl-(L)-3-(3-furyl)-alanyl, (L)-valinyl, N-methyl-(L)-
leucyl, (L)-leucyl] 
8 Peptide 8 (-)-Cyclo-[(L)-leucyl, N-methyl-(L)-phenylalanyl] 
9 Peptide 9 (-)-Cyclo-[N-methyl-(L)-leucyl, (L)-phenylalanyl] 
10 Bisdethiobis(methylthio)-acetylaranotin (BDA) 
11 Bisdethiobis(methylthio)-acetylapoaranotin (BDAA) 
12 Marilone A  
13 Mariline B 
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Fig S1. Structures of isolated metabolites.  
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Peptide 1 and 1’, cyclic tetrapeptide, peptide 1 (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), 
(L)-leucyl, (N-methyl-(L)-phenylalanyl), (L)-valinyl] and peptide 1’ (-)-Cyclo-[(N-methyl-(L)-
3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-phenylalanyl), (L)-leucyl]: white solid (2.5 mg 
L-1), [α] D
23 -133 (c 0.44, MeOH); UV (MeOH) λmax 204 nm (log Є 4.69); IR (ATR) νmax 3345 
(br), 2958, 2871, 1704, 1660, 1511, 1364, 1089 cm-1; 1H NMR and 13C NMR (table 4-1 ); 
LRESIMS m/z 525.5 [M+H]+, m/z 523.9 [M-H]-; HRESIMS m/z 547.2902 [M+Na]+ (calcd. for 
C29H40N4NaO5, 547.2896). 
Peptide 2, cyclic tetrapeptide, (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-furylalanyl, N-
methyl-(L)-phenylalanyl, (L)-valinyl]: white solid (1.5 mg L-1), [α] D
23 -129 (c 0.2, MeOH); UV 
(MeOH) λmax 204 nm (log Є 3.45); IR (ATR) νmax 3330 (br), 2961, 2360, 1704, 1660, 1514, 
1362, 1091 cm-1; 1H NMR and 13C NMR (table 4-2); LRESIMS m/z 559.4 [M+H]+, m/z 557.6 
[M-H]-; HRESIMS m/z 581.2731 [M+Na]+ (calcd. for C32H38N4NaO5, 581.2740). 
Peptide 3, cyclic tetrapeptide, (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-phenylalanyl, N-
methyl-(L)-phenylalanyl, (L)-valinyl]: white solid (1 mg L-1), [α] D
23 -153 (c 0.125, MeOH); 
UV (MeOH) λmax 207 nm (log Є 3.06); IR (ATR) νmax 3329 (br), 2961, 1703, 1659, 1512, 
1362, 1090 cm-1; 1H NMR and 13C NMR (table 4-3); LRESIMS m/z 569.7 [M+H]+, m/z 567.7 
[M-H]-; HRESIMS m/z 569.3119 [M+H]+ (calcd. for C34H41N4O4, 569.3128). 
Peptide 4, cyclic tetrapeptide, (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)- valinyl, (N-
methyl-(L)-3-(3-furyl)-alanyl), (L)- phenylalanyl]: white solid (1.4 mg L-1), [α] D
23 -76 (c 
0.058, MeOH); UV (MeOH) λmax 204 nm (log Є 3.62); IR (ATR) νmax 3331 (br), 2926, 2359, 
1660, 1505, 1386, 1090 cm-1; 1H NMR and 13C NMR (table 4-4); LRESIMS m/z 549.4 
[M+H]+, m/z 547.5 [M-H]-; HRESIMS m/z 571.2532 [M+Na]+ (calcd. for C30H36N4NaO6, 
571.2533). 
Peptide 5 and 5’, cyclic tetrapeptide, peptide 5 (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), 
(L)-3-(3-furyl)-alanyl, (N-methyl-(L)-phenylalanyl), (L)-valinyl] and peptide 5’ (-)-Cyclo-[(N-
methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-phenylalanyl), (L)-3-(3-furyl)-
alanyl]: white solid (0.6 mg L-1), [α] D
23 -110 (c 0.166, MeOH); UV (MeOH) λmax 204 nm (log 
Є 3.41); IR (ATR) νmax 3331 (br), 2925, 2358, 1663, 1515, 1401, 1088 cm
-1; 1H NMR and 13C 
NMR (table 4-5); LRESIMS m/z 549.4 [M+H]+, m/z 547.5 [M-H]-; HRESIMS m/z 571.2526 
[M+Na]+ (calcd. for C30H36N4NaO6, 571.2533). 
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Peptide 6 and 6’, cyclic tetrapeptide, peptide 6 (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-
leucyl, N-methyl-(L)-leucyl, (L)-valinyl] and peptide 6’ (-)-Cyclo-[N-methyl-(L)-phenylalanyl, 
(L)-valinyl, N-methyl-(L)-leucyl, (L)-leucyl]: white solid (0.6 mg L-1), [α] D
23 -105 (c 0.108, 
MeOH); UV (MeOH) λmax 206 nm (log Є 3.03); IR (ATR) νmax 3332 (br), 2957, 2358, 1667, 
1507, 1456 cm-1; 1H NMR and 13C NMR (table 4-6); LRESIMS m/z 501.4 [M+H]+, m/z 499.4 
[M-H]-; HRESIMS m/z 501.3438 [M+H]+ (calcd. for C28H45N4O4, 501.3441). 
Peptide 7 and 7’, cyclic tetrapeptide, peptide 7 (-)-Cyclo-[N-methyl-(L)-3-(3-furyl)-alanyl, 
(L)-leucyl, N-methyl-(L)-leucyl, (L)-valinyl] and peptide 7’ (-)-Cyclo-[N-methyl-(L)-3-(3-
furyl)-alanyl, (L)-valinyl, N-methyl-(L)-leucyl, (L)-leucyl]: white solid (0.6 mg L-1), [α] D
23 -67 
(c 0.083, MeOH); UV (MeOH) λmax 204 nm (log Є 3.12); IR (ATR) νmax 3342 (br), 2924, 2359, 
1714, 1652, 1520, 1365 cm-1; 1H NMR and 13C NMR (table 4-7); LRESIMS m/z 491.9 
[M+H]+, m/z 489.8 [M-H]-; HRESIMS m/z 513.3045 [M+Na]+ (calcd. for C26H42N4NaO5, 
513.3053). 
Peptide 8, diketopiperazine, (-)-Cyclo-[(L)-leucyl, N-methyl-(L)-phenylalanyl]: white solid 
(0.35 mg L-1), [α] D
23 -14 (c 0.083, MeOH); UV (MeOH) λmax 203 nm (log Є 3.12); IR (ATR) 
νmax 3198 (br), 2954, 2924, 2359, 1678, 1455, 1326 cm
-1; 1H NMR and 13C NMR (table 4-8); 
LRESIMS m/z 275.6 [M+H]+, m/z 273.4 [M-H]-; HRESIMS m/z 297.1568 [M+Na]+ (calcd. for 
C16H22N2NaO2, 297.1579). 
Peptide 9, diketopiperazine, (-)-Cyclo-[N-methyl-(L)-leucyl, (L)-phenylalanyl]: white solid 
(0.15 mg L-1), [α] D
23 -241 (c 0.066, MeOH); UV (MeOH) λmax 203 nm (log Є 2.85); IR (ATR) 
νmax 3248 (br), 2925, 2359, 1681, 1455, 1340 cm
-1; 1H NMR and 13C NMR (table 4-9); 
LRESIMS m/z 275.6 [M+H]+, m/z 273.4 [M-H]-; HRESIMS m/z 297.1555 [M+Na]+ (calcd. for 
C15H20N2NaO2, 297.1573). 
Bisdethiobis(methylthio)-acetylaranotin (BDA): amorphous solid (0.5 mg L-1), [α] D
23 -220 
(c 0.092, MeOH) ); UV (MeOH) λmax 230 nm; IR (ATR) νmax 1740, 1676, 1230 cm
-1; 1H NMR 
and 13C NMR (table S1); LREIMS m/z 552.3 [M+H+18]+, molecular formula C24H26O8N2S2. 
Spectral data are in accordance with published data.102,103 
Bisdethiobis(methylthio)-acetylpoaranotin (BDAA): amorphous solid (1.2 mg L-1), [α] D
23 -
275 (c 0.1, MeOH) ); UV (MeOH) λmax 228 and 266 nm; IR (ATR) νmax 1740, 1672, 1241, 750 
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cm-1; 1H NMR and 13C NMR (table S1); LREIMS m/z 536.2 [M+H+18]+, molecular formula 
C24H26O7N2S2. Spectral data are in accordance with published data.
102,103
  
 
 
Fig S2. Isolation scheme for isolated polyketides (marilone A and mariline B) from a 60 day Stachylidium sp. 
culture on biomalt salt agar medium supplemented with [1-
13
C]sodium acetate. 
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8.2 1H and 13C NMR data of isolated metabolites 
Fig S3. 
1
H NMR (300 MHz, CD3COCD3) spectrum of peptide 1 and 1’.  
Peptide 1: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-leucyl, N-methyl-(L)-phenylalanyl, (L)-valinyl] 
Peptide 1’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, N-methyl-(L)-phenylalanyl, (L)-leucyl] 
 
Fig S4. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 1 and 1’. 
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Fig S5. 
1
H NMR (300 MHz, CD3COCD3) spectrum of peptide 2. 
(-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-3-(3-furyl-alanyl), N-methyl-(L)-phenylalanyl, (L)-valinyl] 
 
Fig S6. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 2. 
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Fig S7. 
1
H NMR (300 MHz, CD3COCD3) spectrum of peptide 3. 
(-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-phenylalanyl, N-methyl-(L)-phenylalanyl, (L)-valinyl] 
 
Fig S8. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 3. 
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Fig S9. 
1
H NMR (500 MHz, CD3COCD3) spectrum of peptide 4. 
(-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)- valinyl, (N-methyl-(L)-3-(3-furyl)-alanyl), (L)- phenylalanyl] 
 
Fig S10. 
13
C NMR (125 MHz, CD3COCD3) spectrum of peptide 4. 
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Fig S11. 
1
H NMR (300 MHz, CD3COCD3) spectrum of peptide 5 and 5’. 
Peptide 5: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-3-(3-furyl)-alanyl, (N-methyl-(L)-phenylalanyl), (L)-
valinyl] 
Peptide 5’: (-)-Cyclo-[(N-methyl-(L)-3-(3-furyl)-alanyl), (L)-valinyl, (N-methyl-(L)-phenylalanyl), (L)-3-(3-furyl)-
alanyl] 
 
Fig S12. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 5 and 5’. 
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Fig S13. 
1
H NMR (300 MHz, CD3COCD3) spectrum of peptide 6 and 6’. 
Peptide 6: (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-leucyl, N-methyl-(L)-leucyl, (L)-valinyl] 
Peptide 6’: (-)-Cyclo-[N-methyl-(L)-phenylalanyl, (L)-valinyl, N-methyl-(L)-leucyl, (L)-leucyl] 
 
 
Fig S14. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 6 and 6’. 
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Fig S15. 
1
H NMR (500 MHz, CD3COCD3) spectrum of peptide 7 and 7’. 
Peptide 7: (-)-Cyclo-[N-methyl-(L)-3-(3-furyl)-alanyl, (L)-leucyl, N-methyl-(L)-leucyl, (L)-valinyl] 
Peptide 7’: (-)-Cyclo-[N-methyl-(L)-3-(3-furyl)-alanyl, (L)-valinyl, N-methyl-(L)-leucyl, (L)-leucyl] 
 
 
Fig S16. 
13
C NMR (125 MHz, CD3COCD3) spectrum of peptide 7 and 7’. 
 
Appendix 
129 
 
Fig S17. 
1
H NMR (300 MHz, CD3COCD3) spectrum of peptide 8. 
(-)-Cyclo-[(L)-leucyl, N-methyl-(L)-phenylalanyl] 
 
Fig S18. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 8. 
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Fig S19. 
1
H NMR (500 MHz, CD3COCD3) spectrum of peptide 9. 
(-)-Cyclo-[N-methyl-(L)-leucyl, (L)-phenylalanyl]  
 
 
Fig S20. 
13
C NMR (125 MHz, CD3COCD3) spectrum of peptide 9. 
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Fig S21. 
1
H NMR (300 MHz, CD3COCD3) spectrum of bisdethiobis(methylthio)-acetylaranotin (BDA). 
 
Fig S22. 
13
C NMR (75 MHz, CD3COCD3) spectrum of bisdethiobis(methylthio)-acetylaranotin (BDA). 
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Fig S23. 
1
H NMR (300 MHz, CD3COCD3) spectrum of bisdethiobis(methylthio)-acetylapoaranotin (BDAA). 
 
Fig S24. 
13
C NMR (75 MHz, CD3COCD3) spectrum of bisdethiobis(methylthio)-acetylapoaranotin (BDAA).
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Table S1. 1D NMR spectroscopic data for bisdethiobis(methylthio)-acetylaranotin (BDA) and 
bisdethiobis(methylthio)-acetylapoaranotin (BDAA). 
 BDA
 
BDAA 
Position δC, mult.
a, b
 δH (J in Hz)
a 
δC, mult.
a, b
 δH (J in Hz)
a 
1 165.08, qC - 165.63, qC - 
2  71.70, qC - 75.53, qC - 
3    40.60, CH2 3.20, d (15.4)    40.17, CH2  3.11, t (2.2) 
4 111.93, qC 
3.00, d (15.4) 
- - 
3.16, t (2.2) 
- 
5 138.04, CH 6.73, t (2.2) 119.75, CH 6.02, m 
6 140.52, CH 6.40, dd (8.1, 2.6) 126.29, CH 6.00, m 
7 106.55, CH 4.70, dd (8.4, 1.8) 128.30, CH 5.59, m 
8  72.22, CH 5.74, dt (8.4, 2.2)   75.90, CH 6.70, m 
9  60.97, CH 5.10, d (8.4)   65.21, CH 5.14, d (13.9) 
10 170.17, qC -             170.60, qC - 
11   20.93, CH3 1.99, s     21.31, CH3 2.01, s 
2-SCH3   14.69, CH3 2.25, s    14.35, CH3 2.20, s 
1‘   165.27, qC - 
2‘     71.50, qC - 
3‘     40.96, CH2 3.11, t (2.2) 
4‘   112.12, qC 
3.16, t (2.2) 
- 
5‘   138.07, CH 6.70, d (1.83) 
6‘   140.50, CH 6.39, dd (8.1, 2.2) 
7‘   106.52, CH 4.69, dd (8.1, 1.8) 
8‘     72.30, CH 5.75, dt (8.4, 1.8) 
9‘     61.13, CH 5.06, d (8.0) 
10‘   170.13, qC - 
11‘       20.96, CH3 2.00, s 
2‘-SCH3       14.75, CH3 2.29, s 
a
 CD3COCD3, 300/75 MHz.
 b
 Implied multiplicities determined by DEPT.  
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Fig S25. Key COSY and HMBC correlations of cyclic peptides. 
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8.3 13C NMR data of labeled metabolites 
Fig S26. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 1 and 1’ after feeding [1-
13
C]phenylalanine. 
 
Fig S27. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 3 after feeding [1-
13
C]phenylalanine. 
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Fig S28. Inverse gated 
1
H decoupled 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 1 and 1’ after 
feeding [U-
13
C]glycerol. 
 
Fig S29. Inverse gated 
1
H decoupled 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 1 and 1’ after 
feeding [1-
13
C]glucose. 
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Fig S30. 
13
C NMR (75 MHz, MeOD) spectrum of peptide 1 and 1’ after feeding [Me-
13
C]methionine. 
 
Fig S31. 
13
C NMR (75 MHz, CD3COCD3) spectrum of peptide 1 and 1’ after feeding [1-
13
C]sodium acetate. 
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 Fig S32. 
13
C NMR (75 MHz, CD3COCD3) spectrum of marilone A after feeding [1-
13
C]sodium acetate.
 
Fig S33. 
13
C NMR (75 MHz, CD3COCD3) spectrum of marilone A (taken from literature).
83 
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Fig S34. 
13
C NMR (75 MHz, CD3COCD3) spectrum of mariline B after feeding [1-
13
C]sodium acetate. 
 
Fig S35. 
13
C NMR (75 MHz, CD3COCD3) spectrum of mariline B (taken from literature).
84 
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Table S2. 
13
C-NMR data for [U-
13
C]glycerol-derived peptide 1  (not including phenylalanine moiety). 
C  δc (ppm)  Signal pattern  J
(C,C)
, Hz 
1 170.9, qC dd J
(1,2)
=53.0 
 J
(1,3)
=3.0 
2  62.8, CH dd J
(2,1)
=53.0 
J
(2,3)
=38.0 
3    24.5, CH
2
 dd J
(3,2)
=38.0 
 J
(3,1)
=3.0 
4 122.0, qC dd J
(4,5)
=49.5 
J
(4,7)
=73.0 
5 110.9, CH dd J
(5,4)
=49.5 
 J
(5,7)
=3.0 
6 144.5, CH s - 
7 141.1, CH dd J
(7,4)
=73.0 
 J
(7,5)
=3.0 
9 172.9, qC d J
(9,10)
=54.1 
10  49.3, CH d J
(10,9)
=54.1 
11    42.0, CH
2
 s - 
12  25.0, CH d J
(12,14)
=35.4 
13   22.5, CH
3
 s - 
14    23.2, CH
3
 d J
(14,12)
=35.4 
25 171.8, qC d J
(25,26)
=54.1 
26    56.2, CH d J
(26,25)
=54.1 
27      30.0, CH
2
 NO NO 
28      20.7, CH
3
 d J
(28,27)
=35.4 
29     18.4, CH
3
 s - 
dd: doublet of doublet, d: doublet, s: singlet, NO: not observed 
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Table S3. 
13
C-NMR data for [U-
13
C]glycerol-derived peptide 1’ (not including phenylalanine moiety).     
C  δc (ppm)  Signal pattern  J
(C,C)
,Hz 
1 170.5, qC dd J
(1,2)
=53.0 
 J
(1,3)
=3.0 
2  62.7, CH dd J
(2,1)
=53.0 
J
(2,3)
=38.0 
3    24.5, CH
2
 dd J
(3,2)
=38.0 
 J
(3,1)
=3.0 
4 122.0, qC dd J
(4,5)
=49.5 
J
(4,7)
=73.0 
5 110.9, CH dd J
(5,4)
=49.5 
 J
(5,7)
=3.0 
6 144.5, CH s - 
7 141.1, CH dd J
(7,4)
=73.0 
 J
(7,5)
=3.0 
9 172.2, qC d J
(9,10)
=54.1 
10  56.3, CH d J
(10,9)
=54.1 
11 30.2, CH NO NO 
12   20.8, CH3 d J(12,11)=35.4 
13   18.4, CH
3
 s - 
24 172.5, qC d J
(24,25)
=54.1 
25  49.1, CH d J
(25,24)
=54.1 
26    41.9, CH2 s - 
27  25.0, CH d J
(27,29)
=35.4 
28    22.5, CH
3
 s - 
29    23.3, CH
3
 d J
(29,27)
=35.4 
dd: doublet of doublet, d: doublet, s: singlet, NO: not observed 
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Table S4. 
13
C-NMR chemical shifts and 
13
C enrichments (highlighted boxes) of relevant carbons from 
incorporation of [1-
13
C]sodium acetate into marilone A and mariline B.
83,84  
 
 Marilone A
 
Mariline B 
Position δC, mult.
a,b 
δC, mult.
a,b 
1 168.2, qC 167.3, qC 
2 110.0, qC 116.3, qC 
3 158.0, qC 156.9, qC 
4 120.4, qC 119.3, qC 
5 164.2, qC 161.7, qC 
6 100.8, CH 101.8, CH 
7 154.2, qC 150.0, qC 
8   77.0, CH   56.9, CH 
9   62.1, CH3   18.9, CH3 
10     8.8, CH3   62.1, CH3 
11   20.9, CH3     8.8, CH3 
12 -   43.6, CH2 
13 -
 
  61.7, CH2 
1’   66.5, CH2   66.2, CH2 
2’ 120.1, CH 120.6, CH 
3’ 142.1, qC 141.5, qC 
4’   40.1, CH2   40.1, CH2 
5’   26.9, CH2   27.0, CH2 
6’ 124.6, CH 124.6, CH 
7’ 132.1, qC 132.1, qC 
8’   25.8, CH3   25.8, CH3 
9’   16.7, CH3   16.7, CH3 
10’   17.7, CH3   17.7, CH3 
a
Acetone-d6, 75 MHz. 
b
Implied multiplicities determined by DEPT. 
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8.4 LC-ESIMS data  
Fig S36. LC-ESIMS spectra of crude extract of Stachylidium sp. BMS agar culture (A) control, showing mass 
peak at m/z 525.2  [M+H]
+
, and supplemented with (B) [1-
13
C]
 
phenylalanine, showing major isotopic mass 
peak at m/z 526.1  [M+H+1]
+
 .  
TIC: from Sample 1 (220 cont) of 2013-01-25.wiff (Turbo Spray) Max. 5,9e8 cps.
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TIC: from Sample 2 (220ext.lab) of 2013-01-25.wiff (Turbo Spray) Max. 7,6e8 cps.
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 +Q1: Exp 1, 20,377 to 20,891 min from Sample 2 (220ext.lab) of 2013-01-25.wiff (Turbo Spray) Max. 5,3e5 cps.
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Fig S37.  LC-ESIMS spectra of crude extract of Stachylidium sp. BMS agar culture (A) supplemented with [1-
13
C]
 
phenylalanine, showing isotopic mass peak for peptide 3 at m/z 572.4  [M+H+3]
+
 and (B) control, 
showing mass peak at m/z 569.2  [M+H]
+
 for peptide 3.  
 
TIC: from Sample 6 (220 4 lab) of 2013-01-25.wiff (Turbo Spray) Max. 9,1e8 cps.
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 +Q1: Exp 1, 21,005 to 21,519 min from Sample 6 (220 4 lab) of 2013-01-25.wiff (Turbo Spray) Max. 3,4e6 cps.
150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000
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 +Q1: Exp 2, 21,071 to 21,356 min from Sample 1 (220 cont) of 2013-01-25.wiff (Turbo Spray) Max. 1,7e6 cps.
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 +Q1: Exp 2, 20,716 to 21,137 min from Sample 1 (220.0) of 2012-07-06.wiff (Turbo Spray) Max. 3,2e6 cps.
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
m/z, Da
0,0
2,0e5
4,0e5
6,0e5
8,0e5
1,0e6
1,2e6
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 +Q1: Exp 1, 20,435 to 20,721 min from Sample 5 (1 Sh1) of 2013-12-06.wiff (Turbo Spray) Max. 3,7e6 cps.
150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000
m/z, Da
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 +Q1: Exp 2, 18,617 to 19,074 min from Sample 16 (1PCA) of 2013-10-11.wiff (Turbo Spray) Max. 2,0e6 cps.
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Fig S38. LC-ESIMS spectra of crude extract of Stachylidium sp. BMS agar culture (A) control, supplemented 
with (B) [1,7-
13
C]shikimic acid, (C) 2-chloro-protocatechuic acid and (D) 2-fluoro-4-hydroxybenzoic acid. No 
new ions were observed as compared to control.
 +Q1: Exp 2, 20,475 to 21,077 min from Sample 4 (1FPHBA) of 2013-05-31.wiff (Turbo Spray) Max. 3,9e5 cps.
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 +Q1: Exp 2, 20,716 to 21,137 min from Sample 1 (220.0) of 2012-07-06.wiff (Turbo Spray) Max. 3,2e6 cps.
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
m/z, Da
0,0
2,0e5
4,0e5
6,0e5
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1,0e6
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515,9346,8 378,8 621,8261,5 718,6 753,6251,6
 +Q1: Exp 2, 20,716 to 21,137 min from Sample 3 (220.2) of 2012-07-06.wiff (Turbo Spray) Max. 1,1e6 cps.
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
m/z, Da
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 +Q1: Exp 2, 20,716 to 21,137 min from Sample 4 (220.3) of 2012-07-06.wiff (Turbo Spray) Max. 5,4e5 cps.
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
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Fig S39.  LC-ESIMS spectra of crude extract of Stachylidium sp. BMS agar culture (A) control, and 
supplemented with (B) 2-fluoro-L-phenylalanine, (C) 3-fluoro-L-phenylalanine (D) 4-fluoro-L-phenylalanine 
(E) tyrosine. New ions were observed in (B) and (C) as compared to control culture (A) to which no 
fluorinated phenylalanine was added. (F) Structure of fluorinated phenylalanine substrates and proposed 
new products. 
 +Q1: Exp 2, 20,716 to 21,137 min from Sample 5 (220.4) of 2012-07-06.wiff (Turbo Spray) Max. 4,7e5 cps.
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
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 +Q1: Exp 2, 20,716 to 21,137 min from Sample 7 (220 +Tyr) of 2012-07-06.wiff (Turbo Spray) Max. 4,7e6 cps.
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Fig S40. LC-ESIMS spectrum of marilone A isolated from Stachylidium sp. BMS agar culture supplemented 
with [1-
13
C]sodium acetate, showing major mass peak at m/z 345.2049 [M+H]
+ 
and isotopic peaks indicating 
successful incorporation. 
Fig S41. LC-ESIMS spectrum of mariline B isolated from Stachylidium sp. BMS agar culture supplemented 
with [1-
13
C]sodium acetate, showing major mass peak at m/z 388.5 [M+H]
+
 and isotopic peaks indicating 
successful incorporation. 
TIC: from Sample 4 (6.8 Na) of 2014-02-07.wiff (Turbo Spray) Max. 7,8e8 cps.
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 +Q1: Exp 1, 22,547 to 23,003 min from Sample 4 (6.8 Na) of 2014-02-07.wiff (Turbo Spray) Max. 2,8e6 cps.
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Fig S42. Extracted ion chromatograms (XIC) of a mixture of Marfey’s reagent (FDAA) with (A) L-valine, (B) D-
valine, and (C) hydrolysed peptide 1, 1’ corresponding to molecular mass of L- valine conjugated with 
Marfey’s reagent (FDAA).  
 
XIC of +Q1: Exp 1, 369 to 371 Da from Sample 1 (L-val) of 2014-11-14.wiff (Turbo Spray) Max. 4,5e6 cps.
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XIC of +Q1: Exp 1, 369 to 371 Da from Sample 2 (D-val) of 2014-11-14.wiff (Turbo Spray) Max. 4,4e6 cps.
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XIC of +Q1: Exp 1, 369 to 371 Da from Sample 1 (524.F) of 2015-01-09.wiff (Turbo Spray) Max. 1,6e6 cps.
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Fig S43. Extracted ion chromatograms (XIC) of a mixture of Marfey’s reagent (FDAA) with (A) L-leucine, (B) 
D-leucine, and (C) hydrolysed peptide 1, 1’ corresponding to molecular mass of L-leucine conjugated with 
Marfey’s reagent (FDAA).  
 
 
 
XIC of +Q1: Exp 1, 383 to 385 Da from Sample 4 (L-leu) of 2014-11-14.wiff (Turbo Spray) Max. 5,1e6 cps.
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XIC of +Q1: Exp 1, 383 to 385 Da from Sample 5 (D-leu) of 2014-11-14.wiff (Turbo Spray) Max. 4,3e6 cps.
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XIC of +Q1: Exp 2, 383 to 385 Da from Sample 1 (524.F) of 2015-01-09.wiff (Turbo Spray) Max. 4,9e5 cps.
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Fig S44. Extracted ion chromatograms (XIC) of a mixture of Marfey’s reagent (FDAA) with (A) N-methyl-L-
phenylalanine, (B) N-methyl-D-phenylalanine, and (C) hydrolysed peptide 1, 1’ corresponding to molecular 
mass of N-methyl-L-phenylalanine conjugated with Marfey’s reagent (FDAA).  
 
 
 
XIC of +Q1: Exp 1, 431 to 433 Da from Sample 10 (L-MePhe) of 2014-11-14.wiff (Turbo Spray) Max. 8,6e6 cps.
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XIC of +Q1: Exp 1, 431 to 433 Da from Sample 11 (D-MePhe) of 2014-11-14.wiff (Turbo Spray) Max. 7,5e6 cps.
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XIC of +Q1: Exp 2, 431 to 433 Da from Sample 1 (524.F) of 2015-01-09.wiff (Turbo Spray) Max. 6,1e5 cps.
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Fig S45. Extracted ion chromatograms (XIC) of a mixture of Marfey’s reagent (FDAA) with (A) L-
phenylalanine, (B) D-phenylalanine, and (C) hydrolysed peptide 3 corresponding to molecular mass of L-
phenylalanine conjugated with Marfey’s reagent (FDAA).
XIC of +Q1: Exp 1, 417 to 419 Da from Sample 7 (L-Phe) of 2014-11-14.wiff (Turbo Spray) Max. 4,6e6 cps.
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XIC of +Q1: Exp 1, 417 to 419 Da from Sample 8 (D-Phe) of 2014-11-14.wiff (Turbo Spray) Max. 3,9e6 cps.
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XIC of +Q1: Exp 1, 417 to 419 Da from Sample 14 (524.I) of 2014-11-14.wiff (Turbo Spray) Max. 4,4e5 cps.
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Time, min
0,0
2,0e4
4,0e4
6,0e4
8,0e4
1,0e5
1,2e5
1,4e5
1,6e5
1,8e5
2,0e5
2,2e5
2,4e5
2,6e5
2,8e5
3,0e5
3,2e5
3,4e5
3,6e5
3,8e5
4,0e5
4,2e5
4,4e5
In
te
n
s
it
y
, 
c
p
s
18,37
17,12
3,83
6,741,47 3,19
2,85 4,91 7,42
5,26
0,98 8,39 14,32 19,29 19,86 20,83 25,00
A 
B 
C 
